Official Protocol Title:
NCT number:
Document Date:           31-Oct-2023
[STUDY_ID_REMOVED]
A Single-and Multiple Dose Study to Assess the  Safety, 
Pharmacokinetics  and Pharmacodynamics of 
Subcutaneous MK-2060 in Participants with Chronic 
and/or End-Stage Kidney Disease

PRODUCT: MK-2060 1
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201590] -2023
TITLE PAGE
THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE 
CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & 
DOHME LLC, RAHWAY, NJ, [LOCATION_003] (MSD).
Protocol Title: A Single -and Multiple Dose Study to Assess the Safety, Pharmacokinetics 
and Pharmacodynamics of Subcutaneous MK- 2060 in Participants with Chronic and/or End -
Stage Kidney Disease
Protocol Number: 011-01
Compound Number: MK-2060
Sponsor Name: [CONTACT_19519] & Dohme LLC (hereafter c alled the Sponsor or MSD)
Legal Registered Address:
[ADDRESS_1201591], NJ [ZIP_CODE] [LOCATION_003]
Regulatory Agency Identifying Number(s):
NCT Not applicable
EU CT Not applicable
EudraCT Not applicable
JRCT Not applicable
WHO Not applicable
UTN Not applicable
IND 142,237
Approval Date: [ADDRESS_1201592]: MK-2060 2
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201593] -2023
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor contact [CONTACT_19372] (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date
08V5WQ
PRODUCT: MK-2060 3
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201594] -2022 Not applicable
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: 01
Overall Rationale for the Amendment:
This amendment is primarily issued to include the addition of a multiple dose panel in 
participants with CKD [ADDRESS_1201595] the clinical or regulatory integrity of 
the protocol. All other relevant changes and 
their primary reasons are included for 
completeness.
Section 1.1, Synopsis Change of the hypothesized geometric mean 
AUC0 -∞ from 1130nM*hr to [ZIP_CODE] nM*hr.This change was made to correct a 
typographical error and to align with a 
previously issues 19 -DEC- 2022 PCL #[ADDRESS_1201596]: MK-2060 4
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201597] -2023
Section Number and 
Name [CONTACT_19523] 1.3, Schedule of 
ActivitiesAddition of footnote “ d” to clarify w ording 
regarding the Screening 2 visit Hematology, 
Chemistry, Urinalysis (Lab Safety Tests) .This change was made to align with a 
previously issued 09 -FEB-2023 PCL #4.
Section 1.3, Schedule of 
ActivitiesAddition of footnote “e” to clarify wording 
regardi ng the Screening [ADDRESS_1201598].This change was made to align with a 
previously issued 15 -FEB-2023 PCL #5.
Section 1.3, Schedule of 
ActivitiesAddition of Part [ADDRESS_1201599] of completed clinical studies .This change was made to include new data 
from completed clinical studies.
Section 2.2.3, Ongoing 
Clinical StudiesAddition of study data/information for MK-
2060 -007, MK-2060 -009, MK -2060 -012, 
and MK -2060 -013. This change was made to include new data 
from ongoing clinica l studies.
Section 3, Hypotheses, 
Objectives and EndpointsChange of the hypothesized geometric mean 
AUC0 -∞ from 1130nM*hr to [ZIP_CODE] nM*hr.Refer to Section 1.1 rationale.
Section 4.2, Scientific 
Rationale for Study 
DesignClarifying wording due to addition of a 
multiple dose panel in participants with 
CKD 4 or 5 and a single dose panel in 
participants with ESKD on peritoneal 
dialysis.Refer to Section 1.2 rationale.
Section [IP_ADDRESS], 
Pharmacokinetic 
EndpointsClarifying wor ding due to addition of a 
multiple dose panel in participants with 
CKD [ADDRESS_1201600]: MK-2060 5
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201601] time 
to hemostasis or lead to any bleeding related 
AEs.
Section 5.2, Exclusion 
CriteriaAdded an exclusion criterion surrounding 2
measurements of eGFR (taken at least 
72hours apart) are different by [CONTACT_726] 
30%. This change w as made to ensure participants 
with rapi[INVESTIGATOR_861880].
Section 5.3.2 .1, Caffeine
RestrictionsAdded caffeine restrictions for Part 2 and 
Part 3 and clarified restrictions for Part 1.Refer to Section 1.2 rationale.
Section 6.1, Study 
Intervention(s) 
AdministeredUpdated Table°1 to include information for 
Part 2 and Part 3.Refer to Section 1.2 rationale.
Section 6.3.1, 
Intervention AssignmentAdded intervention assignment information 
for Part 2 and Part 3.Refer to Section 1.2 rationale.
Section 6.5, Concomitant 
TherapyRemoved clopi[INVESTIGATOR_861881].See rationale for Section 5.2.
Section 8.1.7, 
Assignment of 
Treatment/Randomi zation 
NumberUpdated to include information and/or 
wording regarding the addition of Part 2 and 
Part 3.Refer to Section 1.2 rationale.
Section [IP_ADDRESS], Timing 
of Dose AdministrationReduced total dosing time from 2 minutes 
to 1 minute.This change was m ade to decrease the 
allowable study medication administration 
window.
Section 8.1.9, 
Discontinuation and 
WithdrawalUpdated to include information and/or 
wording regarding the addition of Part 2 and 
Part 3.Refer to Section 1.2 rationale.
Section 8.1.11, 
DomicilingUpdated to include information and/or 
wording regarding the addition of Part 2 and 
Part 3.Refer to Section 1.2 rationale.
Section 8.3 .2.1, Resting 
Vital SignsUpdated to include information and/or 
wording regarding the addition of Part 2 and 
Part 3.Refer to Section 1.2 rationale.
Section 8.3.3, 
ElectrocardiogramUpdated to include information and/or 
wording regarding the addition of Part 2 and 
Part 3.Refer to Section 1.2 rationale.
Section 8.3.3, 
ElectrocardiogramChange of allowable procedure window for 
Day 1 predose ECGs from within 24 hour s 
prior to dosing MK -2060/placebo to within 
3hours prior to dosing MK -2060/placebo.This change was made to correct a 
typographical error and to align with a 
previously issued 01 -FEB-2023 PCL #3.
Section 8.3.6 , Hemoccult 
TestClarifying wording surrounding when to 
provide and return hemoccult tests.Refer to Section 8.3.3 rationale.
Section [IP_ADDRESS], Systemic 
Injection Reaction 
AssessmentClarified wording surrounding how long 
participants will be monitored during the 
administration of MK -2060/placebo –now 
participants will be monitored for at least 4 
hours up to 24 to 48 hours postdose at the 
CRU after the initiation of administration.This change was made following 
investigat or/site feedback.
08V5WQ
PRODUCT: MK-2060 6
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201602] -2023
Section Number and 
Name [CONTACT_19523] 8.6.1, Blood 
Collection for Plasma 
MK-2060Removal of statement “Samples taken on 
the day of infusion will be collected in the 
opposite arm from the infusion site.”This change was made to correct a 
typographical error.
Section 8.7, 
PharmacodynamicsClarified wording that sample collection, 
storage, and shipment instructions for 
pharmacodynamic samples will be provided 
in the Study Operations Manual.This change was made to correct a 
typographical error.
Section 8.9, Future 
Biomedical Research 
Sample CollectionClarified what specimens be obtained as 
part of FBR.This change was made to correct a 
typographical error.
Section 8.11 .3, Poststudy Updated to include information and/or 
wording regarding the addition of Part 2 and 
Part 3.Refer to Section 1.2 rationale.
Section 8.11.4, 
Participants Discontinued 
From Study Intervention 
but Continuing to be 
Monitored in the StudyAddition of CKD5 as a possible group of 
participants that may progress to ESKD
during the stud y.Refer to Section 5.1 rationale.
Section 8.11.6, Critical 
Procedures Based on 
Study Objectives: Timing 
of ProcedureUpdated to include information and/or 
wording regarding the addition of Part 2 and 
Part 3.Refer to Section 1.2 rationale.
Section 8.11. 7, Study 
Design/Procedures 
Modifications Permitted 
Within Protocol 
ParametersUpdated to include information and/or 
wording regarding the addition of Part 2 and 
Part 3.Refer to Section 1.2 rationale.
Section 9.4, Analysis 
EndpointsChange of the hypothesized geometric mean 
AUC 0-∞ from [ZIP_CODE] nM*hr to [ZIP_CODE] 
nM*hr .Refer to Section 1.[ADDRESS_1201603] a 
typographical error and toalign with a 
previously issued 11 -NOV- 2022 PCL #1.
Section 10.3, Appendix 3: 
Adverse Events: 
Definitions and 
Procedures for 
Recording, Evaluating, 
Follow -up, and ReportingReplacement of “Sponsor’s product” with 
“Study intervention” throughout the section .This change was made due to incorrect 
standard text.
Section 10. [ADDRESS_1201604]: MK-2060 7
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201605] -2023
TABLE OF CONTENTS
DOCUMENT HISTORY ........................................................................................................3
PROTOCOL AMENDMENT SUMM ARY OF CHANGES ............................................... 3
1 PROTOCOL SUMMARY ............................................................................................ 14
1.1 Synopsis ................................................................................................................. 14
1.2 Schema .................................................................................................................. 19
1.3 Schedule of Activities........................................................................................... 20
1.3.1 Part 1 ............................................................................................................ 20
1.3.2 Part 2 ............................................................................................................ 26
1.3.3 Part 3 ............................................................................................................ 33
2 INTRODUCTION .......................................................................................................... 39
2.1 Study Rationale ....................................................................................................39
2.2 Background .......................................................................................................... 39
2.2.1 Pharmaceutical and Therapeutic Background ............................................. 39
2.2.2 Completed Clinical Studies.......................................................................... 39
2.2.3 Ongoing Clinical Studies ............................................................................. 41
2.3 Benefit/Risk Assessment ...................................................................................... 41
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 42
4 STUDY DESIGN ............................................................................................................ 45
4.1 Overall Design ......................................................................................................45
4.2 Scientific Rationale for Study Design ................................................................ .45
4.2.1 Rationale for Endpoints ............................................................................... 46
[IP_ADDRESS] Safety Endpoints ................................................................................ 46
[IP_ADDRESS] Pharmacokinetic Endpoints ............................................................... 47
[IP_ADDRESS] Pharmacodynamic Endpoints............................................................. 47
[IP_ADDRESS] Planned Exploratory Biomarker Research .........................................48
[IP_ADDRESS].1 Planned Genetic Analysis ........................................................ 48
[IP_ADDRESS] Future Biomedical Research .............................................................. [ADDRESS_1201606]: MK-2060 8
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201607] -2023
[IP_ADDRESS] Caffeine Restrictions .......................................................................... 57
[IP_ADDRESS] Alcohol Restrictions ........................................................................... 57
[IP_ADDRESS] Tobacco Restrictions .......................................................................... 57
5.3.3 Activity Restrictions .................................................................................... 57
5.4 Screen Failures .....................................................................................................58
5.5 Participant Replacement Strategy ......................................................................58
6 STUDY INTERVENTION ............................................................................................ 59
6.1 Study Intervention(s) Administered ...................................................................59
6.2 Preparation/Handling/Storage/Accountability ................................................. 61
6.2.1 Dose Preparation .......................................................................................... 61
6.2.2 Handling, Storage, and Accountabi lity........................................................ 61
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 62
6.3.1 Intervention Assignment.............................................................................. 62
6.3.2 Stratification ................................................................................................ .62
6.3.3 Blinding ........................................................................................................62
6.4 Study Intervention Compliance .......................................................................... 63
6.5 Concomitant Therapy .......................................................................................... 63
6.5.1 Rescue Medications and Supportive Care ................................................... 65
6.6 Dose Modification (Escalation/Titration/Other) ............................................... [ADDRESS_1201608] to Follow -up................................................................................................ .68
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 69
8.1 Administrative and Genera l Procedures ........................................................... 69
8.1.1 Informed Consent ......................................................................................... 69
[IP_ADDRESS] General Informed Consent ................................................................ .70
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 70
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_1201609]: MK-2060 9
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201610] -2023
[IP_ADDRESS] Prior Medications ............................................................................... 71
[IP_ADDRESS] Concomitant Medications ..................................................................71
8.1.6 Assignment of Screening Number ............................................................... 71
8.1.7 Assignment of Treatment/Randomization Number .....................................71
8.1.8 Study Intervention Administration .............................................................. 72
[IP_ADDRESS] Timing of Dose Administration ......................................................... 72
8.1.9 Discontinuation and Withdrawal ................................................................ .72
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 72
8.1.10 Participant Blinding/Unblinding ..................................................................73
8.1.11 Domiciling ...................................................................................................73
8.1.12 Calibration of Equipment ............................................................................. 73
8.2 Efficacy/Immunogenicity Assessments .............................................................. 74
8.3 Safety Assessments ............................................................................................... 74
8.3.1 Physical Examinations ................................................................................. 74
[IP_ADDRESS] Body Weight and Height ...................................................................74
[IP_ADDRESS] Body Mass Index (BMI) ....................................................................74
8.3.2 Vital Signs ....................................................................................................74
[IP_ADDRESS] Resting Vital Signs ............................................................................ 75
[IP_ADDRESS] Orthostatic Vital Signs .......................................................................75
8.3.3 Electrocardiograms ...................................................................................... 75
8.3.4 24-Hour Urine Protein, 24 -Hour Urine Creatinine and Spot Urine 
Collection for Urine Protein: Urine Creatinine Ratio (uPCR) ..................... [ADDRESS_1201611] -Dose ......................... 78
[IP_ADDRESS] Systemic Injection Reaction Assessment........................................... 78
[IP_ADDRESS] Local Injection Reaction Assessment ................................................ 78
8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety 
Events .................................................................................................................... 79
8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Information .......................................................... 80
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events ......82
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information ...82
8.4.4 Regulatory Reporting Requirements for SAE ............................................. 82
8.4.5 Pregnancy and Exposure During Breastfeeding .......................................... 83
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_1201612]: MK-2060 10
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201613] -2023
8.5 Treatment of Overdose ........................................................................................ 84
8.6 Pharmacokinetics ................................................................................................ .84
8.6.1 Blood Collection for Plasma MK- 2060 ....................................................... 84
8.7 Pharmacodynamics .............................................................................................. 84
8.7.1 Blood Collection for PT, aPTT, FXI Activity ............................................. 84
8.7.2 Blood for Plasma ADA ................................................................................ 85
8.8 Biomarkers ........................................................................................................... 85
8.8.1 Planned Genetic Analysis Sample Collection.............................................. 85
8.9 Future Biomedical Research Sample Collection ............................................... 85
8.10 Health Economics Medical Resource Utilization and Health Economics .......85
8.11 Visit Requirements ............................................................................................... 85
8.11.1 Screening ......................................................................................................85
8.11.2 Treatment Period .......................................................................................... 86
8.11.3 Poststudy ......................................................................................................86
8.11.4 Participants Discontinued From Study Intervention but Continuing to be 
Monitored in the Study ................................................................................ 86
8.11.5 Safety Phone Call Follow- Up......................................................................86
8.11.6 Critical Procedures Based on Study Objectives: Tim ing of Procedure .......87
8.11.7 Study Design/Dosing/Procedures Modifications Permitted Within 
Protocol Parameters ..................................................................................... 89
9 STATISTICAL ANALYSIS PLAN ............................................................................. 91
9.1 Statistical Analysis Plan Summary .....................................................................91
9.2 Responsibility for Analyses ................................................................................. 91
9.3 Hypotheses/Estimation ........................................................................................ 91
9.4 Analysis Endpoints ............................................................................................... 91
9.5 Analysis Populations ............................................................................................ 92
9.6 Statistical Methods ............................................................................................... 92
9.7 Interim Analyses ..................................................................................................93
9.8 Multiplicity ........................................................................................................... 93
9.9 Sample Size and Power Calculations ................................................................ .93
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS .....................................................................................................94
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........[ADDRESS_1201614] for Interventional Clinical Trials .....................................94
10.1.2 Financial Disclosure ..................................................................................... 97
10.1.3 Data Protection ............................................................................................. 98
[IP_ADDRESS] Confidentiality of Data ......................................................................98
[IP_ADDRESS] Confidentiality of Par ticipant Records ............................................... 98
[IP_ADDRESS] Confidentiality of IRB/IEC Information ............................................ [ADDRESS_1201615]: MK-2060 11
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201616] -2023
10.1.4 Committees Structure ................................................................................... 99
10.1.5 Publication Policy ........................................................................................ 99
10.1.6 Compliance with Study Registration and Results Posting Requirements ...99
10.1.7 Compliance with Law, Audit, and Debarment .......................................... 100
10.1.8 Data Quality Assurance ............................................................................. 100
10.1.9 Source Documents ..................................................................................... 101
10.1.10 Study and Site Closure ............................................................................... 102
10.2 Appendix 2: Clinical Laboratory Tests ............................................................ 103
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................. 105
10.3.1 Definitions of Medication Error, Misuse, and Abuse ................................ 105
10.3.2 Definition of AE ........................................................................................ 105
10.3.3 Definition of SAE ...................................................................................... 106
10.3.4 Additional Events Reported .......................................................................107
10.3.5 Recording AE and SAE ............................................................................. 108
10.3.6 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ......................................................................................................111
10.4 Appendix 4: Medical Device and Drug –Device Combination Products: 
Product Quality Complaints/Malfunctions: Definitions, Recording, and 
Follow -up............................................................................................................ 112
10.5 Appendix 5: Contraceptiv e Guidance .............................................................. 113
10.5.1 Definitions ..................................................................................................113
10.5.2 Contraceptive Requirements ......................................................................114
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research .......................................................................................... 116
10.7 Appendix 7: Country -specific Requirements .................................................. 120
10.8 Appendix 8: Blood Volume Tables ...................................................................121
10.9 Appendix 9: Algorithm for Assessing Out of Range Laboratory Values .....123
10.10 Appendix 10: Abbreviations ............................................................................. [ADDRESS_1201617]: MK-2060 12
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201618] OF TABLES
Table 1 Study Interventions ...................................................................................... 60
Table 2 Sample Allocation Schedule for Part 1 ........................................................ 62
Table 3 Sample Allocation Schedule for Part 2 ........................................................ 62
Table 4 Sample Allocation Schedule for Part 3 ........................................................ 62
Table 5 Local Injection Reaction Assessment .......................................................... 79
Table 6 Reporting Time Periods and Time Frames for Adverse Events and 
Other Reportable Safety Events ..................................................................81
Table 7 Pharmacokinetic, Pharmacodynamic and Safety (Blood/Urine) 
Collection Windows for Part1 .....................................................................87
Table 8 Pharmacokinetic, Pharmacodynamic and Safety (Blood/Urine) 
Collection Windows for Part 2 ....................................................................88
Table 9 Pharmacokinetic, Pharmacodynamic and Safety (Blood/Urine) 
Collection Windows for Part [ADDRESS_1201619]: MK-2060 13
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201620]: MK-2060 14
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201621] -2023
1 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title: A Single -and Multiple Dose Study to Assess the Safety, Pharmacokinetics 
and Pharmacodynamics of Subcutaneous M K-2060 in Participants with Chronic and/or End -
Stage Kidney Disease
Short Title: MK-2060 PK Study
Acronym: N/A
Hypotheses, Objectives, and Endpoints:
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
This study is to be conducted in adult participants with chronic and/or end- stage kidney 
disease.
Primary Objective s Primary Endpoint s
Part 1: To evaluate the safety and 
tolerability of MK -2060 following single -
dose SC administration in adult participant s 
with Stage 4 or 5Chronic Kidney Disease.
Part 2: To evaluate the safety and 
tolerability of MK -2060 following multiple -
dose SC administration in adult participants 
with Stage 4 or 5 Chronic Kidney Disease.
Part 3: To evaluate the safety and 
tolerabili ty of MK -2060 following single -
dose SC administration in adult participants 
with End- Stage Kidney Disease on 
Peritoneal Dialysis.Bleeding related AEs, AEs ,and 
discontinuations due to AEs
Part 1: To evaluate plasma 
pharmacokinetics of MK -2060 following 
single -dose SC administration in adult 
participants with Stage 4 or 5 Chronic 
Kidney Disease.
Hypothesis:
The true geometric mean of AUC0 -∞ after a 
single well tolerated dose of MK -[ADDRESS_1201622] [ZIP_CODE] nM*hr.Measurement of MK -2060 plasma AUC0-
∞, AUC0 -168, Cmax, C168, Tmax, 
terminal t1/2, CL/F an d Vz/F
08V5WQ
PRODUCT: MK-2060 15
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201623] -2023
Part 2: To evaluate plasma 
pharmacokinetics of MK -2060 following 
multiple -dose SC administration in adult 
participants with Stage 4 or 5 Chronic 
Kidney Disease.
Estimation:
The effect of multiple -dose SC 
administration of MK-2060 in adult 
participants with Stage 4 or 5 Chronic 
Kidney Disease will be estimated.
Part 3: To evaluate plasma 
pharmacokinetics of MK -2060 following 
single -dose SC administration in adult 
participants with End -Stage Kidney Disease 
on Peritoneal Dial ysis.
Estimation:
The effect of single -dose SC administration 
of MK -2060 in adult participants with End 
Stage Kidney Disease on Peritoneal 
Dialysis will be estimated.
Secondary Objective Secondary Endpoint
Part 1: To evaluate the effect of MK -2060 
on aPTT following single dose SC 
administration in adult participants with 
Stage 4 or 5 Chronic Kidney Disease.
Part 2: To evaluate the effect of MK -2060 
on aPTT following multiple -dose SC 
administration in adult particip ants with 
Stage 4 or 5Chronic Kidney Disease.
Part 3: To evaluate the effect of MK -[ADDRESS_1201624]: MK-2060 16
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201625] -2023
Overall Design:
Study Phase Phase 1
Primary Purpose Treatment
Indication Thrombosis
Population Patient: Adult participants with CKD
Study Type Interventional
Intervention Model Single Group
This is a multi site study.
Type of Control Placebo
Study Blinding Double -blind
Blinding Roles Participants or Subjects
Estimated Duration of Study The Sponsor estimates that the study will 
require approximately 16to [ADDRESS_1201626] participant (or their legally 
acceptable representative) provides 
documented informed consent until the last 
participant’s last study -related contact.
Number of Participants:
Approximately 12 participants will be randomized to rec eive MK -2060 or placebo in a 3:1 
ratio (9 active and 3 placebo) in both Part 1 and Part 2 and approximately 9 participants will 
be allocated to receive MK -2060 in Part 3.
Intervention Groups and Duration:
Arm Name [CONTACT_19524](s)Dosage 
Level(s)Route of 
AdministrationRegimen/
Treatment 
Period/
Vaccination 
RegimenUse
MK-2060 MK-2060 15 mg/mL 30 mg SC Part 1: Day 1
Part 2: Days 1, 
2, 3, 4, 8, 15, 
and 22
Part 3: Day 1Test Product
Placebo Placebo Saline 0 mg SC Part 1: Day 1
Part 2: Days 1, 
2, 3, 4, 8, 15, 
and 22Placebo
SC=subcutaneous; USP=[LOCATION_002] Pharmacopeia
Placebo SC (0.9% sodium chloride infusion, USP sterile saline)
08V5WQ
PRODUCT: MK-2060 17
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201627] -2023
Total Number of Intervention Groups/Arms There will be 3 intervention groups.
Duration of Participation Part 1: Each participant will participate in 
the study for approximately [ADDRESS_1201628]. After a screening phase of 
4weeks, each part icipant will receive 
assigned intervention for approximately 
1day. After the end -of-treatment each 
participant will be followed for 
approximately 13 weeks .
Part 2: Each participant will participate in 
the study for approximately [ADDRESS_1201629]. After a screening phase of 
4weeks, each participant will receive 
assigned intervention for approximately 
4weeks ( 4 consecutive days of loading 
doses followed by [CONTACT_861894] x 3). 
After the end-of-treatment each participant 
will be followed for approximately 
13weeks.
Part 3: Each participant will participate in 
the study for approxim ately 23weeks from 
the time the participant provides 
documented informed consent through the 
final contact. After a screening phase of 
4weeks, each participant will receive 
assigned intervention for approximately 
1day. After the end -of-treatment each 
participant will be followed for 
approximately [ADDRESS_1201630]: MK-2060 18
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201631] -2023
Study Governance Committees:
Executive Oversight Committee No
Data Monitoring Committee No
Clinical Adjudication Committee No
There are no governance committees in this study. Regulatory, ethical, and study oversight 
considerations are outlined in Appendix 1.
Study Accepts Healthy Participants: No
A list of abbreviations is in Appendix 10.
08V5WQ
PRODUCT: MK-2060 19
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201632]: MK-2060 20
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201633] -2023
1.3 Schedule of Activities
1.3.1 Part 1
Part 1
Scheduled Time
Day 1 (hours post -
dose)Days
Scheduled Timing
Screening 1
Screening 2a
Predose0 1 4 8 12
2 (D1 24 hrs)
3 (D1 48 hrs)
6 (D1 120 hrs)
(±1 Day)
8 (D1 168 hrs)
11 (±1 Day)
14 (±1 Day)
21 (±2 Days)
28 (±3 Days)
60 (±5 Days)
90 Poststudyb(±5 
Days)
104 Phone 
Follow-upc(±5 
Days)Notes
Administrative 
Procedures
Informed Consent X Sec. 5.1, [IP_ADDRESS]
Informed Consent for 
FBRX Sec. 5.1, [IP_ADDRESS]
Inclusion/Exclusion 
CriteriaX X X Sec. 5.1, 5.2, 8.1.[ADDRESS_1201634] X Sec. 8.1.3
Participant ID Bracelet X Sec. 8.11.2
Medical History X X X Sec. 8.1.4
Assignment of Screening 
Number X Sec. 8.1.6
Assignment of 
Randomization NumberXThe randomization number 
is assigned at the time of 
study drug administration. 
Sec. 5.5, 8.1.7
Prior/Concomitant 
Medication ReviewX--------------------------------------------------------------------------------------------- ------------ ------------- X Sec. 5.2, 6.5, 8.1.5
Safety/Clinic 
Procedures
Full physical examination X X X X X Sec. 8.3.1, 8.3.[ADDRESS_1201635]: MK-2060 21
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201636] -2023
Part 1
Scheduled Time
Day 1 (hours post -
dose)Days
Scheduled Timing
Screening 1
Screening 2a
Predose0 1 4 8 12
2 (D1 24 hrs)
3 (D1 48 hrs)
6 (D1 120 hrs)
(±1 Day)
8 (D1 168 hrs)
11 (±1 Day)
14 (±1 Day)
21 (±2 Days)
28 (±3 Days)
60 (±5 Days)
90 Poststudyb(±5 
Days)
104 Phone 
Follow-upc(±5 
Days)Notes
Targeted physical 
examination X X Sec. 8.3.1, Sec. 8.3.7
Height X Sec. 8.3.1
Weight X XBMI to be taken only at 
Screening 1. Sec. 8.3.1
Orthostatic VS (HR, BP) X X X Sec. [IP_ADDRESS].
Semi -recumbent VS (HR, 
BP)X X-------------------- X X X X X X XDay [ADDRESS_1201637] Meals X--------------- X Sec. 5.3.1.
Domiciling X------------------------------- X Sec. 8.1.11
MK-2060/Placebo 
AdministrationXMK-2060/Placebo will be 
administered SC at Time 0. 
Refer to Sec. 6.2, 8.1.[ADDRESS_1201638]: MK-2060 22
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201639] -2023
Part 1
Scheduled Time
Day 1 (hours post -
dose)Days
Scheduled Timing
Screening 1
Screening 2a
Predose0 1 4 8 12
2 (D1 24 hrs)
3 (D1 48 hrs)
6 (D1 120 hrs)
(±1 Day)
8 (D1 168 hrs)
11 (±1 Day)
14 (±1 Day)
21 (±2 Days)
28 (±3 Days)
60 (±5 Days)
90 Poststudyb(±5 
Days)
104 Phone 
Follow-upc(±5 
Days)Notes
Local Injection Site 
ReactionX X X X X X XNote: Participants who call 
the CRU to report an 
injection site reaction on 
Days 4, 5, and/or 7 may be 
asked to return to the CRU 
as soon as possible for an 
additional assessment. Sec. 
8.3.7.
AE/SAE Review X------------------------------------------------------------------------------- ------------ -------------------------- XAll NSAEs and SAEs will 
be recorded up to 104 -days 
postdose (inclusive). Sec. 
8.4
Laboratory Procedures
Serum hCG ( WOCBP 
only)X X X Appendices 2 and 8
Serum FSH -(WONCBP 
only)X Appendices 2, 5, and 8
HIV, hepatitis B and C 
screen (per site SOP)XSec. 5.2, Appendices [ADDRESS_1201640]: MK-2060 23
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201641] -2023
Part 1
Scheduled Time
Day 1 (hours post -
dose)Days
Scheduled Timing
Screening 1
Screening 2a
Predose0 1 4 8 12
2 (D1 24 hrs)
3 (D1 48 hrs)
6 (D1 120 hrs)
(±1 Day)
8 (D1 168 hrs)
11 (±1 Day)
14 (±1 Day)
21 (±2 Days)
28 (±3 Days)
60 (±5 Days)
90 Poststudyb(±5 
Days)
104 Phone 
Follow-upc(±5 
Days)Notes
Drug and Alcohol Screen 
(per site SOP)X XScreening and predose 
drug/alcohol screen are 
mandatory (predose drug 
screen may occur in the 
evening prior to Day 1 at 
the time of admission); any 
additional drug /alcohol
screen is conducted per site 
SOP. Sec. 8.3.5 and 
Appendix 2
24-Hour Urine Protein 
Collection XThe 24 -hour urine 
collection will begin the 
evening before dosing. Sec. 
8.3.4, Appendix 2.
24-Hour Urine Creatinine 
CollectionXThe 24 -hour urine 
collection will begin the 
evening before dosing. Sec. 
8.3.4, Appendix 2.
Spot Urine Collection for 
Urine Protein: Urine 
Creatinine RatioX X XIf a participant is unable to 
produce a urine sample [ADDRESS_1201642]: MK-2060 24
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201643] -2023
Part 1
Scheduled Time
Day 1 (hours post -
dose)Days
Scheduled Timing
Screening 1
Screening 2a
Predose0 1 4 8 12
2 (D1 24 hrs)
3 (D1 48 hrs)
6 (D1 120 hrs)
(±1 Day)
8 (D1 168 hrs)
11 (±1 Day)
14 (±1 Day)
21 (±2 Days)
28 (±3 Days)
60 (±5 Days)
90 Poststudyb(±5 
Days)
104 Phone 
Follow-upc(±5 
Days)Notes
Hematology, Chemistry, 
UrinalysisX XdX X X X XHematology/Chemistry/Uri
nalysis will be obtained 
after an [ADDRESS_1201644] XeX X X X X X X X Sec. 8.3.6 
Biomarkers
Blood for Genetic 
Analysisf XCollected predose from 
enrolled participants only. 
Sec. 8.8.1, Appendix 8
Pharmacokinetics
Blood for Plasma MK -
2060 X X X X X X X X X X X X XSec. 8.6.1, Appendix 8, and 
Study Operations Manual
Pharmacodynamics
Blood for PT/aPTT/FXI 
activity by [CONTACT_861895] X X X X X X X X X X X XSec. 8.7.1, Appendix 8, and 
Study Operations Manual
Blood for plasma ADAXX X X X XSec. 8.7.2, Appendix 8, and 
Study Operations Manual
08V5WQ
PRODUCT: MK-2060 25
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201645] -2023
Part 1
Scheduled Time
Day 1 (hours post -
dose)Days
Scheduled Timing
Screening 1
Screening 2a
Predose0 1 4 8 12
2 (D1 24 hrs)
3 (D1 48 hrs)
6 (D1 120 hrs)
(±1 Day)
8 (D1 168 hrs)
11 (±1 Day)
14 (±1 Day)
21 (±2 Days)
28 (±3 Days)
60 (±5 Days)
90 Poststudyb(±5 
Days)
104 Phone 
Follow-upc(±5 
Days)Notes
ADA=antidrug antibody; aPTT=activated partial thromboplastin time; AE=adverse event; BMI=body mass index; BP=blood pressure; CRU=clinical research unit; D=Day; 
DNA=deoxyribonucleic acid, ECG=electrocardiogram; FBR=future biomedical research, FSH=follicle s timulating hormone; FXI=factor XI; HIV=human immunodeficiency 
virus; hCG=human chorionic gonadotropin ;HR=heart rate; ID=identification; IEC=Independent Ethics Committee; IRB=Institutional Review Board; NSAE=nonserious adverse 
event; PT=prothrombin time; R R=respi[INVESTIGATOR_697]; SAE=serious adverse event; SC=subcutaneous; SOP=standard operating procedure; VS=vital signs; WOCBP=women of 
childbearing potential; WONCBP=women of nonchildbearing potential
a. Screening [ADDRESS_1201646] study visit may obtained on Day 90 (±5 days)
Follow up on any clinical or laboratory AEs should occur in person if the post study visit occurs prior to [ADDRESS_1201647] study visit. The investigator may 
decide to perform the poststudy visit at the time of discontinuation or as soon as possible after discontinuation as outlined in Section s7.1and 8.1.9 .
c.At the discretion of the investigator an in-person follow- up may be performed.
d. If Screening 2 occurs on Day -1, only obtain predose Hematology, Chemistry, Unrinalysis lab safety tests (these results will be used to satisfy both the Sc reening 2 and 
predose safety lab tests).
e. Hemoccult test will be provided to a participant at Screening 1 visit and returned at Screening 2 visit or prior to dosing at the time scheduled by [CONTACT_093], if Screening 2 
visit does not occur.
f. This sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response. This sample will not be collected at the site if there is
either a local law or regulation prohibiting collection, or if the IRB/IEC does not approve the collection of the sample for this purpose. If the sample is collected, leftover
extracted DNA will be store d for future biomedical research once the participant signs the FBR consent. If the planned genetic analysis is not approved, but FBR is approved and
consent is given, this sample will be collected for the purpose of FBR. Blood for genetic analysis should be collected only once per participant after randomization.
08V5WQ
PRODUCT: MK-2060 26
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201648] -2023
1.3.2 Part 2
Part 2
Screening 
≤[ADDRESS_1201649]-
studyNotes
Scheduled Timing
(Week)
Screening [ADDRESS_1201650] Week 4
Scheduled Timing 
(Day)1 2 3 4 8 10 15 17 22 23 26 29 35 42 49 63 81 111 130
Visit Window 
(Day)NA NA NA NA NA ±1NA ±1NA NA ±1NA ±2±2±2±2±3±3 ±7
Administrative 
Procedures
Informed Consent X Sec. 5.1, [IP_ADDRESS]
Informed Consent 
for FBRX Sec. 5.1, [IP_ADDRESS]
Inclusion/Exclusion 
CriteriaX X X Sec. 5.1, 5.2, 8.1.[ADDRESS_1201651]: MK-2060 27
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201652] -2023
Part 2
Screening 
≤[ADDRESS_1201653]-
studyNotes
Scheduled Timing
(Week)
Screening [ADDRESS_1201654] Week 4
Scheduled Timing 
(Day)1 2 3 4 8 10 15 17 22 23 26 29 35 42 49 63 81 111 130
Visit Window 
(Day)NA NA NA NA NA ±1NA ±1NA NA ±1NA ±2±2±2±2±3±3 ±7
Prior/Concomitant 
Medication ReviewX-------------------------------------------------------------------------------------------- -------------------------- XSec. 5.2, 6.5, 8.1.5
Safety/Clinic 
Procedures
Full physical 
examinationX X X X X X X Sec. 8.3.1, 8.3.7
Targeted physical 
examination X X X X X X Sec. 8.3.1, Sec. 8.3.7
Height X Sec. 8.3.1
Weight X XBMI to be taken only at Screening 
1. Sec. 8.3.1
Orthostatic VS (HR, 
BP)X X X X X XDays 1,4,8, 15 and 22
measurements will be predose; 
Sec. [IP_ADDRESS].
Semi -recumbent VS 
(HR, BP)X X X X X X X X X X X XDays 1, 4, 8, 15 and 22
measurements will be predose;
Sec. 8.3.2
RR and body 
temperatureX X X X X XDays 1, 4, 8, 15 and 22
measurements will be predose; 
Sec. 8.3.2.
08V5WQ
PRODUCT: MK-2060 28
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201655] -2023
Part 2
Screening 
≤[ADDRESS_1201656]-
studyNotes
Scheduled Timing
(Week)
Screening [ADDRESS_1201657] Week 4
Scheduled Timing 
(Day)1 2 3 4 8 10 15 17 22 23 26 29 35 42 49 63 81 111 130
Visit Window 
(Day)NA NA NA NA NA ±1NA ±1NA NA ±1NA ±2±2±2±2±3±3 ±7
12-lead ECG X X X X X X X XDays 1, 4, 8, 15 and 22
measurements will be predose; 
Sec. 8.3.3.
Domiciling X X X X X X X Sec. 8.1.[ADDRESS_1201658] Meals X X X X Sec. 5.3.1.
MK-2060/Placebo 
AdministrationX X X X X X XMK-2060/Placebo will be 
administered SC at Time 0. Refer 
to Sec. 6.2, 8.1.8 and the Study 
Pharmacy Manual for additional 
information on the preparation 
and administration of the study 
drug.
Local Injection Site 
ReactionX X X X X X X X X X XNote: Participants who call the 
CRU to report an injection site 
reaction on non-visit days may be 
asked to return to the CRU as 
soon as possible for an additional 
assessment. Sec. 8.3.7.
08V5WQ
PRODUCT: MK-2060 29
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201659] -2023
Part 2
Screening 
≤[ADDRESS_1201660]-
studyNotes
Scheduled Timing
(Week)
Screening [ADDRESS_1201661] Week 4
Scheduled Timing 
(Day)1 2 3 4 8 10 15 17 22 23 26 29 35 42 49 63 81 111 130
Visit Window 
(Day)NA NA NA NA NA ±1NA ±1NA NA ±1NA ±2±2±2±2±3±3 ±7
AE/SAE Review X---------------------------------------------------------------------------------------------------------------------- XAll NSAEs and SAEs will be 
recorded up to 1 44-days postdose 
(inclusive). Sec. 8.4 .
Laboratory 
Procedures
Serum hCG 
(WOCBP only)X X X X Appendices 2 and 8
Serum FSH -
(WONCBP only)X Appendices 2, 5, and 8
HIV, Hepatitis B 
and C screen (per 
site SOP)X Sec. 5.2, Appendices 2 and 8
Drug and Alcohol 
Screen (per site 
SOP)X XScreening and predose 
drug/alcohol screen are 
mandatory (predose drug screen 
may occur in the evening prior to 
Day 1 at the time of admission); 
any additional drug screen is 
conducted per site SOP. Sec. 
8.3.[ADDRESS_1201662]: MK-2060 30
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201663] -2023
Part 2
Screening 
≤[ADDRESS_1201664]-
studyNotes
Scheduled Timing
(Week)
Screening [ADDRESS_1201665] Week 4
Scheduled Timing 
(Day)1 2 3 4 8 10 15 17 22 23 26 29 35 42 49 63 81 111 130
Visit Window 
(Day)NA NA NA NA NA ±1NA ±1NA NA ±1NA ±2±2±2±2±3±3 ±7
24-Hour Urine 
Protein Collection XThe 24 -hour urine collection will 
begin the evening before dosing. 
Sec. 8.3.4, Appendix 2.
24-Hour Urine 
Creatinine 
CollectionXThe 24 -hour urine collection will 
begin the evening before dosing. 
Sec. 8.3.4, Appendix 2.
Spot Urine 
Collection for Urine 
Protein: Urine 
Creatinine RatioX X XIf a participant is unable to 
produce a urine sample at Day 1 
12-hours postdose, this spot urine 
can be collected the next time the 
participant is able to void. Sec. 
8.3.4, Appendix 2 .
Hematology, 
Chemistry, 
UrinalysisX XdX X X X X X X X X X XHematology/Chemistry/Urinalysis 
will be obtained after an [ADDRESS_1201666]: MK-2060 31
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201667] -2023
Part 2
Screening 
≤[ADDRESS_1201668]-
studyNotes
Scheduled Timing
(Week)
Screening [ADDRESS_1201669] Week 4
Scheduled Timing 
(Day)1 2 3 4 8 10 15 17 22 23 26 29 35 42 49 63 81 111 130
Visit Window 
(Day)NA NA NA NA NA ±1NA ±1NA NA ±1NA ±2±2±2±2±3±3 ±[ADDRESS_1201670] XeX X XXXXX X XXXXXX X Sec. 8.3.6 .
Biomarkers
Blood for Genetic 
Analysisf XCollected predose from enrolled 
participants only. Sec. 8.8.1, 
Appendix 8
Pharmacokinetics
Blood for Plasma 
MK-2060X X X X X X X X X X X X X X X X XDays 1, 2, 4, 8, 15, and 22 
samples will be predose. Sec. 
8.6.1, Appendix 8, and Study 
Operations Manual
Pharmacodynamics
Blood for 
PT/aPTT/FXI 
activity by [CONTACT_861896] X X X X X X X X X X X X X X X XDays 1, 2, 4, 8, 15, and [ADDRESS_1201671]: MK-2060 32
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201672] -2023
Part 2
Screening 
≤[ADDRESS_1201673]-
studyNotes
Scheduled Timing
(Week)
Screening [ADDRESS_1201674] Week 4
Scheduled Timing 
(Day)1 2 3 4 8 10 15 17 22 23 26 29 35 42 49 63 81 111 130
Visit Window 
(Day)NA NA NA NA NA ±1NA ±1NA NA ±1NA ±2±2±2±2±3±3 ±7
ADA=antidrug antibody; aPTT=activated partial thromboplastin time; AE=adverse event; BMI=body mass index; BP=blood pressure; CRU=clinical research unit; D=Day; 
DNA=deoxyribonucleic acid, ECG=electrocardiogram; FBR=future biomedical research, FSH=follicle stimulating hormone; FXI=facto r XI; HIV=human immunodeficiency 
virus; hCG=human c horionic gonadotropin ;HR=heart rate; ID=identification; IEC=Independent Ethics Committee; IRB=Institutional Review Board; NSAE=nonserious adverse 
event; PT=prothrombin time; RR=respi[INVESTIGATOR_697]; SAE=serious adverse event; SC=subcutaneous; SOP=standard operating procedure ; VS=vital signs; WOCB P=women of 
childbearing potential; WONCBP=women of nonchildbearing potential
a. Screening [ADDRESS_1201675] study visit may obtained on Day 130(±7days)
Follow up on any clinical or laboratory AEs should occur in person if the post study visit occurs prior to 130days following administration of study drug. If a participant 
discontinues for any reason at any time during the course of the study theparticipant may be asked to return to the clinic to complete the post study visit. The investig ator may 
decide to perform the poststudy visit at the time of discontinuation or as soon as possible after discontinuation as outlined in Section s7.1and 8.1.9 .
c.At the discretion of the investigator an in-person follow- up may be performed.
d. If Screen ing 2 occurs on Day -1, only obtain predose Hematology, Chemistry, Unrinalysis lab safety tests (these results will be used to satisfy both the Sc reening 2 and 
predose safety lab tests).
e. Hemoccult test will be provided to a participant at Screening 1 vi sit and returned at Screening 2 visit or prior to dosing at the time scheduled by [CONTACT_093], if Screening 2 
visit does not occur.
f. This sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response. This sample will not be collected at the site if there is
either a local law or regulation prohibiting collection, or if the IRB/IEC does not approve the collection of the sample for this purpose. If the sample is collected, leftover
extracted DN A will be stored for future biomedical research once the participant signs the FBR consent. If the planned genetic analysis is not approved, but FBR is approved and
consent is given, this sample will be collected for the purpose of FBR. Blood for genetic a nalysis should be collected only once per participant after randomization.
08V5WQ
PRODUCT: MK-2060 33
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201676] -2023
1.3.3 Part 3
Part 3
Scheduled Time
Day 1 (hours post -
dose)Days
Scheduled Timing
Screening 1
Screening 2a
Predose0 1 4 8 12
2 (D1 24 hrs)
3 (D1 48 hrs)
6 (D1 120 hrs)
(±1 Day)
8 (D1 168 hrs)
11 (±1 Day)
14 (±1 Day)
21 (±2 Days)
28 (±3 Days)
42 (±4 Days)
60 (±5 Days)
90 (±5 Days)
120 Poststudyb
(±5 Days)
134 Phone 
Follow-upc(±5 
Days)Notes
Administrative 
Procedures
Informed Consent X Sec. 5.1, [IP_ADDRESS]
Informed Consent for 
FBRX Sec. 5.1, [IP_ADDRESS]
Inclusion/Exclusion 
CriteriaX X X Sec. 5.1, 5.2, 8.1.[ADDRESS_1201677] X Sec. 8.1.3
Participant ID Bracelet X Sec. 8.11.2
Medical History XXX Sec. 8.1.4
Assignment of 
Screening Number X Sec. 8.1.6
Assignment of 
Randomization 
NumberXThe allocation number is 
assigned at the time of 
study drug 
administration. Sec. 5.5, 
8.1.7
Prior/Concomitant 
Medication ReviewX--------------------------------------------------------------------------------------------- ------------ ------ --------------- XSec. 5.2, 6.5, 8.1.5
Safety/Clinic 
Procedures
Full physical 
examinationX X X X X Sec. 8.3.1, 8.3.[ADDRESS_1201678]: MK-2060 34
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201679] -2023
Part 3
Scheduled Time
Day 1 (hours post -
dose)Days
Scheduled Timing
Screening 1
Screening 2a
Predose0 1 4 8 12
2 (D1 24 hrs)
3 (D1 48 hrs)
6 (D1 120 hrs)
(±1 Day)
8 (D1 168 hrs)
11 (±1 Day)
14 (±1 Day)
21 (±2 Days)
28 (±3 Days)
42 (±4 Days)
60 (±5 Days)
90 (±5 Days)
120 Poststudyb
(±5 Days)
134 Phone 
Follow-upc(±5 
Days)Notes
Targeted physical 
examination X X Sec. 8.3.1, Sec. 8.3.7
Height X Sec. 8.3.1
Weight X XBMI to be taken only at 
Screening 1. Sec. 8.3.1
Orthostatic VS (HR, 
BP)X X X Sec. [IP_ADDRESS].
Semi -recumbent VS 
(HR, BP)X X-------------------- X X X X X X X XDay [ADDRESS_1201680] Meals X--------------- X Sec. 5.3.1.
Domiciling X------------------------------- X Sec. 8.1.11
MK-2060/Placebo 
AdministrationXMK-2060/Placebo will 
be administered SC at 
Time 0. Refer to Sec. 
6.2, 8.1.[ADDRESS_1201681]: MK-2060 35
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201682] -2023
Part 3
Scheduled Time
Day 1 (hours post -
dose)Days
Scheduled Timing
Screening 1
Screening 2a
Predose0 1 4 8 12
2 (D1 24 hrs)
3 (D1 48 hrs)
6 (D1 120 hrs)
(±1 Day)
8 (D1 168 hrs)
11 (±1 Day)
14 (±1 Day)
21 (±2 Days)
28 (±3 Days)
42 (±4 Days)
60 (±5 Days)
90 (±5 Days)
120 Poststudyb
(±5 Days)
134 Phone 
Follow-upc(±5 
Days)Notes
Local Injection Site 
ReactionX X X X X X XNote: Participants who 
call the CRU to report an 
injection site reaction on 
Days 4, 5, and/or 7 may 
be asked to return to the 
CRU as soon as possible 
for an additional 
assessment. Sec. 8.3.7.
AE/SAE Review X------------------------------------------------------------------------------- ------------ --------------------- -------------- XAll NSAEs and SAEs 
will be recorded up to 
104-days postdose 
(inclusive). Sec. 8.4
Laboratory 
Procedures
Serum hCG ( WOCBP 
only)X X X Appendices 2 and 8
Serum FSH -
(WONCBP only)X Appendices 2, 5, and 8
HIV, hepatitis B and C 
screen (per site SOP)XSec. 5.2, Appendices [ADDRESS_1201683]: MK-2060 36
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201684] -2023
Part 3
Scheduled Time
Day 1 (hours post -
dose)Days
Scheduled Timing
Screening 1
Screening 2a
Predose0 1 4 8 12
2 (D1 24 hrs)
3 (D1 48 hrs)
6 (D1 120 hrs)
(±1 Day)
8 (D1 168 hrs)
11 (±1 Day)
14 (±1 Day)
21 (±2 Days)
28 (±3 Days)
42 (±4 Days)
60 (±5 Days)
90 (±5 Days)
120 Poststudyb
(±5 Days)
134 Phone 
Follow-upc(±5 
Days)Notes
Drug and Alcohol 
Screen (per site SOP)X XScreening and predose 
drug/alcohol screen are 
mandatory (predose drug 
screen may occur in the 
evening prior to Day 1 at 
the time of admission); 
any additional 
drug/alcohol screen is 
conducted per site SOP. 
Sec. 8.3.5 and Appendix 
2
Hematology and
ChemistryX XdX X X X XHematology/Chemistry 
will be obtained after an 
8-hour fast. Predose tests 
can be conducted up to 
[ADDRESS_1201685]: MK-2060 37
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201686] -2023
Part 3
Scheduled Time
Day 1 (hours post -
dose)Days
Scheduled Timing
Screening 1
Screening 2a
Predose0 1 4 8 12
2 (D1 24 hrs)
3 (D1 48 hrs)
6 (D1 120 hrs)
(±1 Day)
8 (D1 168 hrs)
11 (±1 Day)
14 (±1 Day)
21 (±2 Days)
28 (±3 Days)
42 (±4 Days)
60 (±5 Days)
90 (±5 Days)
120 Poststudyb
(±5 Days)
134 Phone 
Follow-upc(±5 
Days)Notes
Biomarkers
Blood for Genetic 
Analysisf XCollected predose from 
enrolled participants 
only. Sec. 8.8.1, 
Appendix 8
Pharmacokinetics
Blood for Plasma MK -
2060 X X X X X X X X X X X X X X XSec. 8.6.1, Appendix 8, 
and Study Operations 
Manual
Pharmacodynamics
Blood for 
PT/aPTT/FXI activity 
by [CONTACT_861895] X X X X X X X X X X X X X XSec. 8.7.1, Appendix 8, 
and Study Operations 
Manual
Blood for plasma 
ADAX X X X X X X XSec. 8.7.2, Appendix 8, 
and Study Operations 
Manual
08V5WQ
PRODUCT: MK-2060 38
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201687] -2023
Part 3
Scheduled Time
Day 1 (hours post -
dose)Days
Scheduled Timing
Screening 1
Screening 2a
Predose0 1 4 8 12
2 (D1 24 hrs)
3 (D1 48 hrs)
6 (D1 120 hrs)
(±1 Day)
8 (D1 168 hrs)
11 (±1 Day)
14 (±1 Day)
21 (±2 Days)
28 (±3 Days)
42 (±4 Days)
60 (±5 Days)
90 (±5 Days)
120 Poststudyb
(±5 Days)
134 Phone 
Follow-upc(±5 
Days)Notes
ADA=antidrug antibody; aPTT=activated partial thromboplastin time; AE=adverse event; BMI=body mass index; BP=blood pressure; CRU=clinical research unit; D=Day; 
DNA=deoxyribonucleic acid, ECG=electrocardiogram; FBR=future biomedical research, FSH=follicle stimulating hormone; FXI=factor XI; HIV=human immunodeficiency 
virus; hCG=human c horionic gonadotropin ;HR=heart rate; ID=identification; IEC=Independent Ethics Committee; IRB=Institutional Review Board; NSAE=nonserious adverse 
event; PT=prothrombin time; RR=respi[INVESTIGATOR_697]; SAE=serious adverse event; SC=subcutaneous; SOP=standard operating procedure ; VS=vital signs; WOCBP=women of 
childbearing potential; WONCBP=women of nonchildbearing potential
a. Scree ning [ADDRESS_1201688] study visit may obtained on Day 120(±5 days)
Follow up on any clinical or laboratory AEs should occur in person if the post study visit occurs prior to [ADDRESS_1201689] study visit. The investigator may 
decide to perform the poststudy visit at the time of discontinuation or as soon as possible after discontinuation as outlined in Section s7.1and 8.1.9 .
c.At the discretion of the investigator an in-person follow- up may be performed.
d. If Screening 2 occurs on Day -1, only obtain predose Hematology and Chemistry lab safety tests (these results will be used to satisfy both the Screening 2 and predose safety 
lab tests).
e. Hemoccult test will be provided to a participant at Screening 1 visit and returned at Screening 2 visit or prior to dosing at the time scheduled by [CONTACT_20603], if Screening 2 
visit does not occur.
f. This sample should be drawn for planned analysis of the association between genetic variants in DNA and drug response. This s ample will not be collected at the site if there is
either a local law or regulation prohibiting collection, or if the IRB/IEC does not approve the collection of the sample for this purpose. If the sample i s collected, leftover
extracted DNA will be stored for future biomedical research once the participant signs the FBR consent. If the planned genetic analysis is not approved, but FBR is approved and
consent is given, this sample will be collected for the purpose of FBR. Blood for genetic analysis should be collected only o nce per participant after randomiz ation.
08V5WQ
PRODUCT: MK-2060 39
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201690] on hemostasis. Hence, targeting FXI is an attractive option to expand 
the therapeutic window for anticoagulat ionin CKD and ESKD patients . The purpose of this 
study is to evaluate the safety, PK and pharmacodynamics of a single and multiple SC dose s
of MK -2060 in participants with Stage 4 and Stage 5 CKD (CKD4 and CKD5) , and ESKD
on peritoneal dialysis. Characterizing SC dosing in this study will help to broaden the Phase 
[ADDRESS_1201691] of the coagulation cascade. MK -2060 is 
an anti -FXI monoclonal antibody being developed for the prevention of thrombotic events in 
CKD/ ESKD . Based on preclinical and human genetic data, as well as emerging clinical data 
using an AS approach [Buller, H. R., et al 2015] [Bethune, C., et al 2017] , FXI inhibition is 
predicted to confer a clinically relevant antithrombotic effect with a reduced risk of bleedin g 
complications and hence an expanded therapeutic index compared to inhibition of more 
downstream clotting factors such as FXa and thrombin. Therefore, FXI/FXIa inhibition is a 
promising therapeutic approach for the prevention of thromboembolic events.
2.2.2 Com pleted Clinical Studies
Study MK -2060- 001:
Study MK -2060- P001 was a double -blind, randomized, placebo -controlled, single site, 
sequential panel study to evaluate the safety, tolerability, PK, and pharmacodynamics of 
single ascending dose administration of SC and IV doses of MK -2060 in healthy male 
participants. Forty- five healthy male participants received single doses of MK -2060 up to 
120 mg administered SC (27 participants) or 40 mg IV (18 participants). MK -[ADDRESS_1201692]: MK-2060 40
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201693] -2023
generally well tolerated and there were no SAEs or discontinuations due to AEs. In healthy 
male participants single IV doses of 20 mg and 40 mg of MK- 2060 resulted in increases in 
aPTT  baseline within 1 hour of administration (  FXI activity inhibition), with aPTT 
remaining  baseline for  hours. 
MK-2060- 004:
MK-2060- 004 w as a 2- part, double -blind, randomized, placebo- controlled, multiple -site, 
sequential- panel, single and multiple dose study in adult male and female ESKD participants 
on hemodialysis. The study evaluated the safety, PK and pharmacodynamics of IV 
administrat ion of single -dose (8, 20 or 40 mg) and multiple dose (25 -mg loading dose 
followed by [CONTACT_861897] 3 weeks) MK- 2060. A total of 38 participants were enrolled. 
Single doses up to 40 -mg and multiple 25 -mg doses were generally well tolerated. Two 
participant s discontinued the study due to a drug -related SAE of lower GI hemorrhage 
(placebo) and nondrug -related AE of COVID -19 infection. A total of 4 SAEs (myocardial 
infarction, GI hemorrhage, pneumonia, and AV graft thrombosis) were reported in 4 
participants ( n=1 in MK -2060 group and n=3 placebo group, respectively). The investigator 
deemed the myocardial infarction as not related to study intervention as the event occurred 
approximately [ADDRESS_1201694] dose of MK -2060. Intervention- related AEs reported in 
participants who received MK -2060 included orthostatic hypotension, headache, 
chromaturia, hematuria, AV fistula hemorrhage, sneezing, and nausea. Anti- drug antibody 
assessment was positive in 2 participants of which neither participant reported AEs after 
showing a positive response to MK -2060.
PK data following single and multiple doses showed a t1/[ADDRESS_1201695] on PT was observed.
MK-2060- 008:
MK-2060- 008 was a Phase 1, open -label, multi- site multiple -dose study to evaluate the 
safety and tolerability of coadministered IV MK -2060 and clopi[INVESTIGATOR_861882] (male and 
female) participants with ESKD on HD. Follo wing a 14- day run in period, participant on 
clopi[INVESTIGATOR_861883] a loading dose of [ADDRESS_1201696]: MK-2060 41
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201697] -2023
2.2.3 Ongoing Clinical Studies
MK-2060- 007:
MK-2060- 007 is an event driven, randomized, placebo -controlled, parallel- group, multi -site, 
double -blind study of MK -2060 in participants with ESKD receiving hemodialysis via an 
AVG. This Phase 2 study is designed to evaluate the efficacy and safety of MK -2060 20 mg 
QW and MK- 2060 6 mg QW (with 3 loading doses in Week 1). As of 10-S ep-2023, [ADDRESS_1201698] been dosed with a 
maximum exposure of 687 days. MK -2060- 007 is ongoing and safety data are blinded and 
preliminary.
MK-2060- 009:
This is a Phase 1 randomized, placebo -controlled, single -ascending dose clinical study to 
evaluate the safety, PK, and pharmacodynamics of IV MK-2060 in healthy Chinese male 
adult participants. As of 10-S ep-2023, 3 panels of 12 participants each (9 MK -2060: 3 
placebo) were administered single 8 mg, 20 mg, and 40 mg IV doses of MK -2060 or placebo 
(9:3). Twenty- four (24)participants in Panel A -B have completed their last visit and all 
assessments . The estimated LPLV is 28- Oct-2023.
MK-2060- 012:
This is a P hase 1 randomized, placebo -controlled single -dose clinical study to evaluate the 
safety, tolerability, PK,and pharmacodynamics of IV MK-2060 in Japanese older 
participants with end -stage kidney disease on dialysis. As of 10-S ep-2023, 17 participants 
were administered a single 50 mg IV dose of MK or placebo (3:1 ratio). LPI[INVESTIGATOR_861884] 07-Feb-2024.
MK-2060- 013
This is a randomized, placebo- controlled, single -ascending dose clinical study to evaluate 
safety, tolerability, PK and pharmacodynamics of MK -2060 in healthy Japanese adult 
participants. As of 10-Sep-2023, 4 panels of 12 participants each ( 3:1 ratio) were 
administered single 8 mg, 20 mg, and 50 mg IV doses of MK -2060, and 30 mg SC dose of 
MK-2060, or placebo (3:1 ratio) .LPLV: is estimated 18-D ec-2023
2.3 Benefit/Risk Assessment
Participants in clinical studies will not receive direct benefit from treatment during 
participation as clinical studies are designed to provide information about the safety and 
properties of an investigational medicine. 
Additional details regarding speci fic benefits and risks for participants participating in this 
clinical study may be found in the accompanying IB and informed consent documents.
08V5WQ
PRODUCT: MK-2060 42
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201699] -2023
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
This study is to be conducted in adult participants with chronic and/or end- stage kidney 
disease.
Primary Objective s Primary Endpoint s
Part 1: To evaluate the safety and 
tolerability of MK -2060 following single -
dose SC administration in adult participants 
with Stage 4 or 5Chronic Kidney Disease.
Part 2: To evaluate the safety and 
tolerability of MK -2060 following multiple -
dose SC administration in adult participants 
with Stage 4 or 5 Chronic Kidney Disease.
Part 3: To evaluate the safe ty and 
tolerability of MK -2060 following single -
dose SC administration in adult participants 
with End- Stage Kidney Disease on 
Peritoneal Dialysis.Bleeding related AEs, AEs ,and 
discontinuations due to AEs
Part 1: To evaluate plasma 
pharmacokinetics of MK -2060 following 
single -dose SC administration in adult 
participants with Stage 4 or 5 Chronic 
Kidney Disease.
Hypothesis:
The true geometric mean of AUC0 -∞ after a 
single well tolerated dose of MK -[ADDRESS_1201700] [ZIP_CODE] nM*hr.
Part 2: To evaluate plasma 
pharmacokinetics of MK -2060 following 
multiple -dose SC administration in adult 
participants with Stage 4 or 5 Chronic 
Kidney Disease.
Estimation:
The effect of multiple -dose SC 
administration of MK -2060 in adult 
participants with Stage 4 or 5 Chronic 
Kidney Disease will be estimated.Measurement of MK -2060 plasma AUC0-
∞, AUC0 -168, Cmax, C168, Tmax,
terminal t1/2, CL/F and Vz/F
08V5WQ
PRODUCT: MK-2060 43
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201701] -2023
Part 3: To evaluate plasma 
pharmacokinetics of MK -2060 following 
single -dose SC administration in adult 
participants with End -Stage Kidney Dis ease 
on Peritoneal Dialysis.
Estimation:
The effect of single -dose SC administration 
of MK -2060 in adult participants with End 
Stage Kidney Disease on Peritoneal 
Dialysis will be estimated.
Secondary Objective Secondary Endpoint
Part 1: To evaluate the effect of MK -2060 
on aPTT following single dose SC 
administration in adult participants with 
Stage 4 or 5 Chronic Kidney Disease.
Part 2: To evaluate the effect of MK -2060 
on aPTT following multiple -dose SC 
administration in adult particip ants with 
Stage 4 or 5Chronic Kidney Disease.
Part 3: To evaluate the effect of MK -2060 
on aPTT following single dose SC 
administration in adult participants with 
End- Stage Kidney Disease on Peritoneal 
Dialysis .aPTT fold change from baseline
Tertiary /Exploratory Objective s Tertiary /Exploratory Endpoint s
Parts 1 and 3: To explore the effect of MK -
2060 on Factor XI (FXI) activity levels 
following a single SC dose.
Part 2: To explore the effect of MK -2060 on 
Factor XI (FXI) activity levels foll owing 
multiple SC dose s.FXI activity level fold change from baseline
Parts 1 and 3: To explore the effect of MK -
2060 on prothrombin time (PT) following a 
single SC dose.
Part 2: To explore the effect of MK -2060 on 
prothrombin time (PT) following multiple
SC dose s.PT fold change from baseline
08V5WQ
PRODUCT: MK-2060 44
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201702] -2023
To explore the relationship between genetic 
variation and response to the treatment(s) 
administered, and mechanisms of disease. 
Variation a cross the human genome may be 
analyzed for association with clinical data 
collected in this study.Germline genetic variation and association 
to clinical data collected in this study
To explore the development and impact of 
ADAs measured in blood samples after
single and multiple SC dose sof MK -2060 is 
administered in adult participants with 
Chronic and/or End -Stage Kidney Disease.ADAs
08V5WQ
PRODUCT: MK-2060 45
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201703] -2023
4 STUDY DESIGN
4.1 Overall Design
This is a 3- part, multi- site, randomized, double -blind, placebo -controlled, single -dose and 
multiple -dose study to assess the safety, tolerability, PK and pharmacodynamics of SC MK -
2060 in participants with CKD4 , CKD5 , and ESKD on Peritoneal Dialysis.
In Part 1, participants with CKD 4 or CKD5 (eGFR from 10 to 29) (n=12) will be randomized 
in a 3:1 ratio to receive a single 30 -mg SC dose of MK -2060 (n=9) or placebo (n=3). 
In Part 2, participants with CKD4 or CKD5 (n= 12) will be randomized in a 3:1 ratio to 
receive 4 loading dose sof 30 mg SC MK -2060 or placebo (given daily for 4 days) followed 
by 30 mg SC MK -2060 (n=9) or placebo (n=3) every week for [ADDRESS_1201704] study visit may enroll in 
Part2 provided screening criteria are met.
In Part 3 ,an open label study, participants with ESKD who are on peritoneal dialysis will 
receive a single 30 mg SCdose of MK -2060 (n=9) .
In all [ADDRESS_1201705] been evaluated in healthy participants 
dosed both via SC and IV administration (P001), and in ESKD -HD participants with IV 
dosing (P004 and P008). Ongoing Phase [ADDRESS_1201706]: MK-2060 46
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201707] -2023
doses of MK- 2060 in healthy Chinese and Japanese participants (P009 and P013), IV doses 
in Japanese dialysis patients (P012), and SC doses in healthy Japanese participants (P013).
An ongoing Phase 2b study (P007) is evaluating the safety and efficacy of MK- [ADDRESS_1201708] IV dose tested in the Phase 2b study is 
20mg IV. Because severe CKD patients not yet on dialysis (ie, CKD4, CKD5) may also 
derive a benefit from inhibition of FXI, enrollment of these patients in a Phase 3 study is 
warran ted. In Phase 3, MK -2060 will be dosed IV in ESKD -HD patients due to the simplicity 
of IV administration during hemodialysis sessions. However, dosing in CKD4 and CKD5 
patients not yet on dialysis will require SC administration, and SC PK has not yet been 
characterized in these patients. For patients wit h ESKD on peritoneal dialysis, IV 
administration is not practical , and enrollment of this patient population in Phase 3 requires 
an assessment of safety and PK of SC doses of MK- 2060 in ESKD .Globally ,approximately 
11% of ESKD patients use peritoneal dial ysis, with higher rates of utilization in some regions
and therefore it is important to include this population so that they can also be candidates for 
MK-[ADDRESS_1201709] ed degree of 
interindividual PK variability. The AUC0 -∞ for a single 30 mg SC dose in CKD4 patients is 
projected to be [ZIP_CODE] nM*hr with 30% GCV. These numbers are based on estimated 
bioavailability  and other PK parameters using data from SC dosing of MK -2060 in 
P001 (NHV) and P004 ( ESKD -HD patients). In Part 2, preliminary analysis of PK and 
pharmacodynamic data from Part [ADDRESS_1201710] 
comparison of PK for this dose between CKD4/CKD5 and dialysis pa tients and the single 30 
mg SC dose given to Japanese NHVs in P013. PK parameters will be estimated for Parts 2 
and 3 and SC dose projection will be further modified based on emerging data .
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Safety Endpoints
Based on the data from P001 (healthy participant study) , P004 ( ESKD on HD study), P008 
(ESKD on HD coadministered with Clopi[INVESTIGATOR_7745] ),and P007 (ongoing Phase 2 study in ESKD
on HD with AVG) along with preclinical safety data, it is expected that single dose SC 
administration of MK -2060 will be well -tolerated in participants with CKD and ESKD . 
Physical examinations, VS, ECGs, laboratory safety tests (serum chemistry and hematology), 
aPTT, PT, and AEs related to bleeding will be assessed throughout the treatment period. 
AEs, including local infusion site reactions and systemic reactions to MK -[ADDRESS_1201711]: MK-2060 47
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201712] -2023
Bleeding related AEs will include any sign or symptom of bleeding, even if not requiring 
intervention by a medical/healthcar e professional, as well as clinically relevant nonmajor 
bleeding or major bleeding. As with all biologic medications, MK -[ADDRESS_1201713] as severe headache, nausea, vomiting, back pain, fever, 
hypotension and multiorgan failure. The risk of any of these reactions to MK -2060 is 
considered low given its profile in preclinical safety studies. There were no infusion 
reactions, no acute hypersensitivity reactions, and no cytokine release reactions observed 
thus far in any MK- 2060 clinical studies. See the IB for more information on the Phase 1 
clinical study experience with MK -2060.
Anti -drug antibodies to MK -2060
The presence and titer of ADAs may be measured using validated assays. ADAs can develop 
to biologics like MK -2060. ADAs may be clinically inconsequential or ma y change the PK 
and/or drug efficacy. Moreover, ADAs may lead to safety events, such as acute or delayed 
hypersensitivity reactions. Thus, the titer of ADAs will be correlated with PK and safety 
events.
[IP_ADDRESS] Pharmacokinetic Endpoints
Plasma PK of MK -[ADDRESS_1201714] er to characterize the PK profile of MK -2060 PK in adults with CKD and ESKD ,
noncompartmental PK parameters including AUC0 -∞, AUC0 -168, Cmax, C168, Tmax, 
terminal t1/2, CL/F, and Vz/F will be summarized after single -and multiple -dose SC 
administration.
[IP_ADDRESS] Pharmacodynamic Endpoints
aPTT, PT and FXI activity (performed by [CONTACT_221452])
In order to assess pharmacodynamics, this study will include an assessment of aPTT 
prolongation levels (relative to baseline), PT and FXI activity levels, with assays performed 
ata Central Laboratory. For PK/pharmacodynamics modeling, aPTT and FXI activity levels 
will be related to plasma exposure. The time points for pharmacodynamics data collection are 
based on the projected PK profile of MK -2060. PK and pharmacodynamics measure ments 
will allow comparison to PK/pharmacodynamics modeling targets at steady state.
08V5WQ
PRODUCT: MK-2060 48
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201715] -2023
[IP_ADDRESS] Planned Exploratory Biomarker Research
[IP_ADDRESS].[ADDRESS_1201716] a participant’s response to therapy, susceptibility to, severity, 
and progression of disease. Variable response to therapy may be due to genetic determinants 
that impact drug ADME; mechanism of action of the drug; disease etiology; and/or 
molecular subtype of the disease being treated. Therefore, where local regulations and 
IRB/IEC allow, a sample will be collected for DNA analysis from consenting participants.
DNA samples may be used for research related to the study intervention(s), the disease under 
study, or related diseases. They may also be used to develop tests/assays including diagnostic 
tests related to the disease under study, related diseases, and study intervention(s). Genetic 
research may consist of the analysis of 1 or more candidate genes, the analysis of genetic 
markers throughout the genome, or an alysis of the entire genome. Analysis may be 
conducted if it is hypothesized that this may help further understand the clinical data.
The samples may be analyzed as part of a multistudy assessment of genetic factors involved 
in the response to understand s tudy disease or related conditions.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct FBR on DNA specimens for which consent was provided during 
this clinical study.
Such research is for biomarker testing to address emergent questions not described elsew here 
in the protocol and will only be conducted on specimens from appropriately consented 
participants. The objective of collecting/retaining specimens for FBR is to explore and 
identify biomarkers that inform the scientific understanding of diseases and/o r their 
therapeutic treatments. The overarching goal is to use such information to develop safer, 
more effective drugs/vaccines, and/or to ensure participants receive the correct dose of the 
correct drug/vaccine at the correct time. The details of FBR are presented in Appendix 6.
4.2.[ADDRESS_1201717] ives and/or to 
08V5WQ
PRODUCT: MK-2060 49
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201718]  of CKD4 patients. The 
30-mg single SC dose of MK- 2060 is anticipated to result in a geometric mean Cmax of 
approximately  and AUC0- ∞ of [ZIP_CODE] nM*hr. These numbers are based upon 
preliminary population PK modeling of observed PK of single SC doses in P001 and 
observed PK in ESKD -HD participants in P004. The projected exposures assume a 
bioavailability observed in SC dosing of MK -2060 in P001 NHV (SC/IV GMR for AUC0 -∞ 
and AUC0 -last were , respectively), and a t1/2 observed in ESKD -HD patients 
after IV administration (P004, ).
These exposures are significantly lower than the chronic toxicology NOAEL (Cmax 
approximately , AUC0- 168 =  from the 4- week rhesus monkey 
toxicity study at 60 mg/kg/week). In P004 (Part 2), where ESKD -HD patients received 
multiple QW [ADDRESS_1201719] comparison of PK for this dose between CKD4/CKD5 and dialysis 
patients and the single [ADDRESS_1201720] participant (or their legally acceptable representative) 
provides documented informed consent. The overall study ends when the last participant 
completes the last study- related contact, withdraws consent, or is lost to follow- up (Section 
7.3).For purposes of analysis and reporting, the overall study ends when the Sponsor 
receives the last laboratory test result or at the time of final contact [CONTACT_26355] , 
whichever comes last.
If the study includes countries in the European Economic Area (EEA), the local start of the 
study in the EEA is defined as First Site Ready (FSR) in any Member State.
A study may be paused during review of newly available preclinica l/clinical safety, PK, 
pharmacodynamic, efficacy, or biologic data or other items of interest, prior to a final 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
08V5WQ
PRODUCT: MK-2060 50
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201721] -2023
decision on continuation or termination of the study. It may be necessary to keep the study 
open for gathering/reviewing of additional supportive data to optimally complete the 
objective(s) of the study. If necessary, the appropriate amendment(s) to the protocol and/or 
appropriate communication(s) will be generated. If the decision has been made to end the 
study following this review period, the s tudy end will be defined as the date of the Sponsor 
decision, and this end of study date supersedes the definitions outlined above. The 
Competent Authority(ies) and IRB(s)/IEC(s) will be apprised of the maximum duration of 
the study beyond the last partici pant out and the justification for keepi[INVESTIGATOR_88635].
4.4.1 Clinical Criteria for Early Study Termination
There are no prespecified criteria for terminating the study early. A primary objective of this 
early Phase 1 study is to identify a safe and well- tolerated dose and/or dosing regimen that 
achieve PK, pharmacodynamic, and/or biologic targets in humans based on preclinical or 
early clinical data. Therefore, it is possible that study participants may not receive all doses 
specified in the protocol if this objective is achieved at lesser dose levels in this study. This 
would not be defined as early termination of the study, but rather an earlier than anticipated 
achievement of the study objective(s). If a finding (eg, PK, pharmacodynamic, efficacy, 
biologic targets, etc) from another preclinical or clinical study using the study intervention(s), 
comparator(s), drug(s) of the same class, or methodology(ies) used in this study results in the 
study(ies) or program being stopped for nonsafety reasons, th is also does not meet the 
definition of early study termination.
Early study termination is defined as a permanent discontinuation of the study due to 
unanticipated concerns of safety to the study participants arising from clinical or preclinical 
studies w ith the study intervention(s), comparator(s), drug(s) of the same class, or 
methodology(ies) used in this study.
The clinical study may be terminated early if the extent (incidence and/or severity) of 
emerging effects/clinical endpoints is such that the ri sk/benefit ratio to the study population 
as a whole is unacceptable. In addition, further recruitment in the study or at (a) particular 
study site(s) may be stopped due to insufficient compliance with the protocol, GCP, and/or 
other applicable regulatory r equirements, procedure -related problems or the number of 
discontinuations for administrative reasons is too high.
08V5WQ
PRODUCT: MK-2060 51
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201722] for Clinical Trials ( Appendix 1.1), this study includes 
participants of varying age (as applicable) , race, ethnicity, and sex (as applicable) . The 
collection and use of these demographic data will follow all local laws and participant 
confidentiality guidelines while supporting the study of the disease, its related factors, and 
the IMP under investigation.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
An individual iseligible for inclusion in the study if the individual meets all of the following 
criteria :
Type of Participant and Disease Characteristics
1.At the time of screening, the participant has CKD 4 or 5 (Part s 1 and 2), or ESKD on 
Peritoneal Dialysis (Part 3) .with a baseline estimated eGFR of 10 to 29mL/min/1.73 m2
based on the 2021 CKD -EPI [INVESTIGATOR_8850] (Parts 1 and 2) .CDK 4 isdefined as an eGFR from 
15 to 29 mL/min/1.73 m2. While CKD5 is defined as eGFR <15, not on dialysis , only 
CKD5 participants with an eGFR from 10 to 14 mL/min/1.73 m2will be enrolled as thes e 
patients are likely to be more stable than those with eGFR<10 and less likely to transition 
to dialysis during the time frame of the study .
CKD -EPI [INVESTIGATOR_8850]:
eGFRcr = 142 x min(Scr/κ, 1)α x max(Scr/κ, 1) -1.200 x 0.9938Age x 1.012 [if female]
where:
Scr = standardized serum creatinine in mg/dL
κ = 0.7 (females) or 0.9 (males)
α = -0.241 (female) or - 0.302 (male)
min(Scr/κ, 1) is the minimum of Scr/κ or 1.0
max(Scr/κ, 1) is the maximum of Scr/κ or 1.0
Age (years)
Baseline eGFR will be obtained twice (at least 72 hours apart as a part of participant 
screening), and the mean of the two values will be used. The 2 values used should not differ 
by [CONTACT_726] 30%. The second bas eline eGFR may be obtained at the time of check in. 
08V5WQ
PRODUCT: MK-2060 52
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201723] of, 
or in con junction with, the estimate of the eGFR.
2.The participant has a BMI ≥18 and ≤45 kg/m2. See Section [IP_ADDRESS] for criteria on 
rounding to the nearest whole number. BMI=weight (kg)/height (m)2.
3.Baseline health of the participant is judged to be stable based on medical history, physical 
examination, vital sign measurements, and ECGs performed prior to 
randomization/allocation.
4.The participant has liver function test (ALT and AST) results equal to or below 1.5x 
ULN and deemed not clinically significant by [CONTACT_229587].
Demographics
5.The participant is male or female, from [ADDRESS_1201724] one of the following conditions applies:
•Not a WOCBP
OR
•A WOCBP and:
-Uses an acceptable contraceptive method, or be abstinent from heterosexual 
intercourse as their preferred and usual lifestyle (abstinent on a long -term and 
persistent basis), as described in Appendix [ADDRESS_1201725] dose of study intervention. The investigator should 
evaluate the potential for contraceptive method failure (ie, noncompliance, recently 
initiated) in relationship to the first dose of study intervention. Contraceptive use by 
[CONTACT_301792] .
-Has a negative highly sensitive pregnancy test (serum as required by [CONTACT_13125]) within [ADDRESS_1201726]: MK-2060 53
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201727] be documented by [CONTACT_2299]’s dated signature [CONTACT_861909] a 
consent form along with the dated signature [CONTACT_63564].
A copy of the signed and dated consent form should be given to the participant before 
participation in the study.
The initial informed consent form, any subsequent revised written informed co nsent form 
and any written information provided to the participant must receive the IRB/ERC’s 
approval/favorable opi[INVESTIGATOR_19349]. The participant should be informed in a timely 
manner if new information becomes available that may be relevant to t he participant’s 
willingness to continue participation in the study. The communication of this information 
will be provided and documented via a revised consent form or addendum to the original 
consent form that captures the participant’s dated signature d ated signature.
Specifics about a study and the study population will be added to the consent form template 
at the protocol level.
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations 
and Sponsor requirements.
5.[ADDRESS_1201728] be excluded from the study if the individual meets any of the following 
criteria :
Medical Conditions
1.The participant has a history of clinically significant concomitant disease or condition 
(including treatment for such conditions) or diseases whose current condition is 
considered clinically unstable (with the exception of stable CKD) that, in the opi[INVESTIGATOR_13046], could either interfere with the study drug, compromise interpretation of 
study data, or pose an u nacceptable risk to the patient. Participants with a remote history 
of uncomplicated medical events (eg, childhood asthma) may be enrolled in the study at 
the discretion of the investigator.
2.The participant has rapi[INVESTIGATOR_861885]. Rapi[INVESTIGATOR_121252] > 30% difference between 
2measurements of eGFR taken at least [ADDRESS_1201729]: MK-2060 54
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201730] -2023
3.The participant is mentally or legally incapacitated, has significa nt emotional problems at 
the time of pre -study (screening) visit or expected during the conduct of the study or has 
a history of clinically significant psychiatric disorder of the last [ADDRESS_1201731] had situational depression may be enroll ed in the study at the discretion of the 
investigator.
4.The participant has a history of cancer (malignancy), including adenocarcinoma.
Exceptions: (1) Participants with adequately treated non -melanomatous skin carcinoma may 
participate in the study; or car cinoma in situ of the cervix or; (2) Participants with other  
malignancies which have been successfully treated ≥ 5 years prior to the prestudy (screening) 
visit where, in the judgement of both the investigator and treating physician, appropriate 
follow -uphas revealed no evidence of recurrence from the time of treatment through the time 
of the prestudy (screening) visit; or (3) Participants, who, in the opi[INVESTIGATOR_656327], are highly unlikely to sustain a recurrence for the duration of the s tudy
5.The participant has blood coagulation test (aPTT, PT) ≥20 % outside of normal range on 
prestudy (Screening), which are considered clinically significant by [CONTACT_258995].
6.The participant has any other clinically significant abnormalities in laboratory test results 
at screening that would, in the opi[INVESTIGATOR_871], increase the participant’s risk 
of participation, jeopardize complete participation in the study, or compromise 
interpretation of study data.
7.The participant has a history of deep vein thrombosis or pulmonary embolism. Has a 
history of vascular access thrombosis within 1 month prior to enrollment. Has a personal 
or family history of bleeding disorder (eg, hemophilia, Factor V Leiden, prothrombin 
gene mutation, protein C or S deficiency, ATIII deficiency, anti -phospholipid Ab 
syndrome).
8.The participant has a history of GI bleeding, duodenal polyps or gastric ulcer in the last [ADDRESS_1201732] 3 months or 
active gingivitis.
10.The participant has ongoing anticoagulant therapy (warfarin, api[INVESTIGATOR_3822], dabigatran, 
rivaroxaban, edoxaban, betrixaban) or antiplatelet therapy (prasugrel, ticagrelor, 
ticlopi[INVESTIGATOR_5325]). Aspi[INVESTIGATOR_282502].
11.At the time of screening or pre -dose, the participant has planned significant dental 
procedures (including planned dental surgery), or other planned surgical procedures 
within duration of participation of study.
12.The participant is positive for hepatitis B surface antigen or HIV. Participants positive for 
hepatitis C antibodies may be enrolled with agreement of both investigator and sponsor. 
Positive test(s) for HBsAg, hepatitis C antibodies or HIV.
13.The part icipant had a major surgery and/or donated or lost 1 unit of blood (approximately 
500 mL) within 4 weeks prior to the pre -study (screening) visit.
14.The participant has a history of significant multiple and/or severe allergies (e.g., food, 
drug, latex allerg y), or has had an anaphylactic reaction or significant intolerability (i.e., 
systemic allergic reaction) to prescription or non -prescription drugs or food.
08V5WQ
PRODUCT: MK-2060 55
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201733] -2023
15.The participant has a tattoo, scar, or other physical finding at the area of the injection that 
woul d interfere with the injection or a local tolerability assessment.
16.The participant has a history (participant recall) of receiving any human immunoglobulin 
preparation such as IVIG or RhoGAM within the last year.
17.The participant has a history (participant recall) of receiving any biological therapy 
(including human blood products or monoclonal antibodies; excluding erythropoietin and 
insulin) within the last 3 months or 5 half -lives (whichever is longer), or vaccination 
within the last 1 month.
Exceptions:
•Participants who have received seasonal flu vaccine and pneumococcal vaccine within 
the last 1 month may be enrolled at the discretion of the investigator.
•COVID- [ADDRESS_1201734] 48 hours prior to any COVID- 19 vaccination. 
Investigational COVID -19 vaccines (ie, those not licensed or approved for Emergency 
Use) are not allowed.
18.Exclusion criteria for ECG:
•Heart rate <40 or >110 bpm
•QTc interval >500 msec
•Any significant arrhythmia or conduction abnormality, (including but not specific to 
atrioventricular block [2nddegree or higher], Wolff Parkinson White syndrome [unless 
curative radio ablation therapy]), which, in the opi[INVESTIGATOR_110409],
could interfere with the safety for the individual patient.
Prior/Concomitant Therapy
19.The participant is unable to refrain from or anticipates the use of any medication, 
including prescription and nonprescription drugs or herbal remedies beginning 
approxi mately 2 weeks (or 5 half -lives) prior to administration of the initial dose of study 
intervention, throughout the study (including washout intervals between treatment 
periods), until the poststudy visit. There may be certain medications that are permitted to 
treat chronic conditions and/or conditions associated with kidney disease if the 
participant has been on a stable regimen for approximately [ADDRESS_1201735] other injectable medications (i e, 
insulin, GLP -1 analogs) for which the participant has been on a stable regimen in a 
location other than where the study medication/placebo is injected (see Section 6.5).
Prior/Concurrent Clinical Study Experience
20.The participant has been in another inve stigational study within 4 weeks (or 5 half -lives, 
whichever is greater) prior to the sponsor’s investigational drug (MK -2060) 
administration. The window will be derived from the date of the last dose in the previous 
study.
08V5WQ
PRODUCT: MK-2060 56
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201736] -2023
Diagnostic Assessments
21.The parti cipant has a BP >190 mmHg systolic or >110 mmHg diastolic.
Other Exclusions
22.The participant is under the age of legal consent.
23.The participant consumes greater than 3 servings of alcoholic beverages (1 serving is 
approximately equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or 
distilled spi[INVESTIGATOR_2120] [29.5 mL/1 ounce]) per day. Participants who consume 4 servings of 
alcoholic beverages per day may be enrolled at the discretion of the investigator.
24.The participant consumes excessive amounts, define d as greater than 6 servings (1 
serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy 
drinks, or other caffeinated beverages per day.
25.The participant is a regular user of any illicit drugs or has a history of drug (includi ng 
alcohol) abuse within approximately [ADDRESS_1201737] a negative serum or 
saliva drug screen prior to randomization. Participants with a positive drug screen due to 
the use of physician prescribed medications (eg, opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651],
antidepressants) may be enrolled at the discretion of the investigator. In addition, 
participants with a positive THC may be enrolled at the discretion of the investigator if 
the participants’ THC use is under 4 times/month and the participants agree to n ot use 
during their study participation. Participants with positive THC on screening may have 
rechecks performed at the discretion of the investigator to ensure compliance with 
abstinence from THC use during study participation.
26.The participant is unwillin g to comply with the study restrictions (see Section 5.3 for a 
complete summary of study restrictions).
27.The investigator has any concern regarding safe participation in the study or for any other 
reason the investigator considers the participant inappropriate for participation in the 
study.
28.Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
5.[ADDRESS_1201738] until 2 hours after 
study drug/placebo administration when they will be given breakfast. Br eakfast will be 
administered approximately [ADDRESS_1201739] -dose; lunch and dinner will be provided at ~ 4- and 
08V5WQ
PRODUCT: MK-2060 57
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201740] -2023
~ 10-hours postdose respectively. Additional meals and snack(s) will be provided by [CONTACT_861898]. Participan ts will fast from all food and 
drinks, except water, between meals and snacks. After the [ADDRESS_1201741] been completed, subsequent meals and snacks will be unrestricted in 
caloric content, composition, and timing.
Instructions on whether to take MK -2060 with or without food and/or drink may be modified 
during the study based on newly available data.
5.3.2 Caffeine, Alcohol, and Tobacco Restrictions
[IP_ADDRESS] Caffeine Restrictions
For Parts [ADDRESS_1201742] dose of study intervention administration. At all other tim es, 
caffeinated beverages or xanthine -containing products will be limited to no more than 6 units 
per day (1 unit = 120 mg of caffeine).
[IP_ADDRESS] Alcohol Restrictions
Participants will refrain from consumption of alcohol 24 hours before the pre -study and 
poststudy visits and from 24 hours before and after study intervention administration in each 
treatment period. 
Participants will refrain from consumption of alcohol 12 hours prior to scheduled outpatient 
visits.
At all other times, alcohol consumption is limited t o no more than approximately 3 alcoholic 
beverages or equivalent servings (1 serving is approximately equivalent to: beer [354 mL/12 
ounces], wine [118 mL/4 ounces], or distilled spi[INVESTIGATOR_2120] [29.5 mL/1 ounce]) per day.
[IP_ADDRESS] Tobacco Restrictions
Smoking (and/or the use of nicotine/nicotine -containing products) is permitted during the 
study. Participants should follow the CRU’s smoking restrictions during domiciling.
5.3.3 Activity Restrictions
Participants will avoid unaccustomed strenuous physical activity (i.e., weightlifting, running, 
bicycling, etc.) from the pre -study (screening) visit until administration of the initial dose of 
study intervention, throughout the study (including washout intervals between treatment 
periods) and until the poststudy visit.
08V5WQ
PRODUCT: MK-2060 58
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201743] -2023
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently randomized in the study. A minimal set of screen failure information 
may be included, as outlined in the eCRF entry guidelines. Minimal information may include 
demography, screen failure details, eligibility criteria, and any AEs or SAEs meeting 
reporting requirements.
5.5 Participant Replacement Strategy
If a participant discontinues from study intervention or withdraws from the study within 21 
days after dosing a replacement participant may be enrolled if deemed appropriate by [CONTACT_198340]. The replacement participant will generally receive the same 
intervention or intervention sequence (as appropriate) as the particip ant being replaced. The 
replacement participant will be assigned a unique treatment/randomization number.
The replacement participant may begin dosing at the subsequent dose level for that panel, 
based on investigator and Sponsor review and discussion.
08V5WQ
PRODUCT: MK-2060 59
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201744] -2023
6 STU DY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to 
the study protocol.
Clinical supplies MK-2060 will be packaged to support enrollment and replacement 
participants as required. When a replacement participant is required, the Sponsor or designee 
needs to be contact[CONTACT_100915]. Clinical supplies will be 
affixed with a clinical l abel in accordance with regulatory requirements.
6.1 Study Intervention(s) Administered
The study interventions to be used in this study areoutlined in Table 1.
Country- specific requirements are noted in Appendix [ADDRESS_1201745]: MK-2060 60
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201746] -2023
Table 1 Study Interventions
Arm 
NameArm Type Intervention 
NameIntervention 
TypeDose 
FormulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
AdministrationRegimen/
Treatment 
Period/
Vaccination 
RegimenUse IMP or 
NIMP/
AxMPSourcing
MK-2060 Experimental MK-2060 Drug Powder 15 mg/mL 30 mg SC Part 1: Day 1
Part 2: Days 
1, 2, 3, 4, 8, 
15, and 22
Part 3: Day 1Test 
ProductIMP Provided by 
[CONTACT_861899] 0 mg SC Part 1: Day 1
Part 2: Days 
1, 2, 3, 4, 8, 
15, and 22Placebo IMP Locally
EEA=European Economic Area; IMP=investigational medicinal product; NIMP /AxMP =noninvestigational/ auxiliary medicinal product; SC=subcutaneous .
The classification of IMP and NIMP /AxMP in this table is based on guidance issued by [CONTACT_19411]. Country differences 
with respect to the definition/classification of IMP and NIMP /AxMP may exist. In these circumstances, local legislation is followed.
In this protocol, placebo is diluent alone (normal saline); diluent is used for blinding purposes and does not contain active ingredients.
08V5WQ
PRODUCT: MK-2060 61
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201747] -2023
All supplies indicated in Table 1will be provided per the “Sourcing” column depending on 
local country operational requirements. If local sourcing, every attempt should be made to 
source these supplies from a single lot/batc h number where possible (eg, not applicable in the 
case where multiple lots or batches may be required due to the length of the study, etc) .
Refer to Section 8.1.8 for details regarding administration of the study intervention.
6.2 Preparation/Handling/Storage /Accountability
6.2.[ADDRESS_1201748] be stored 
in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country Sponsor personnel or designee will provide appropr iate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_19333] (if applicable) as per local guidelines unless otherwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any applicable laws and regulations.
08V5WQ
PRODUCT: MK-2060 62
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201749] -2023
6.3 Meas ures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Participants will be assigned randomly according to a computer -generated allocation 
schedule. Sample allocation schedule sareshown below in Table 2 , Table 3, and Table 4 .
Table 2 Sample Allocation Schedule for Part 1
Treatment Group Participants Dose
1 n=9 MK-2060 30 mg SC
2 n=3 Placebo
n=number of participants; SC=subcutaneous
Table 3 Sample Allocation Schedule for Part 2
Treatment Group ParticipantsaDose
1 n=9 MK-2060 30 mg SC
2 n=3 Placebo
a. To ensure a minimum of 3 CDK 4 and CKD 5 participants receive MK -2060, a ssignment of randomization numbers for 
CKD4 participants will occur in ascending order (starting block) . Assignment of randomization number for CKD5 
participants will occur in descending order (ending block) .
n=number of participants; SC=subcutaneous
Table 4 Sample Allocation Schedule for Part 3
Treatment Group Participants Dose
1 n=9 MK-2060 30 mg SC
n=number of participants; SC=subcutaneous
6.3.2 Stratification
No stratification based on age, sex, or other characteristics will be used in this study.
6.3.3 Blinding
For this study a double -blinding technique will be used. MK- 2060 and placebo will be 
prepared and/or dispensed in a blinded fashion by [CONTACT_344403]- site personnel. The participant, the investigator, and Sponsor personnel or delegate(s) 
who are involved in the study intervention administration or clinical evaluation of the 
participants are unaware of the intervention assignments.
See Section 8.1.[ADDRESS_1201750]: MK-2060 63
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201751] dose of study drug in each panel of the study. The name (generic 
and brand), dose and regimen for all concomitant medications sho uld be recorded on the 
appropriate CRF.
All medications must be reviewed and approved by [CONTACT_861185].  This list is not exhaustive, but serves as a guideline to 
facilitate the approval process b etween the investigator and the Sponsor clinical monitor
ALLOWED MEDICATIONS
Lipid Lowering Agents: Statins
Lipid Lowering Agents: Fibrates
Lipid Lowering Agents: Other
Ezetimibe
Anti -Hypertensive Medications:
Monotherapy and combination therapy with an AC E inhibitor, an angiotensin II receptor 
antagonist, beta blockers, calcium channel blockers, or a diuretic is allowed in the study.
Specific therapeutic categories include:
1.ACE inhibitors
2.Angiotensin II Receptor Antagonists
08V5WQ
PRODUCT: MK-2060 64
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201752] -2023
3.Diuretics
4.Beta -blockers
5.Calcium channel- blockers
Diabetes Medications
Specific therapeutic categories include:
6.Insulin
7.Metformin
8.Sulfonylureas 
9.Meglitinides
10.Thiazolidinediones
11.DPP- 4 Inhibitors
12.GLP -1 Analogs
Aspi[INVESTIGATOR_861886]-dose aspi[INVESTIGATOR_861887].
Clopi[INVESTIGATOR_861888] P008 .
Iron
Phosphate Binders
Vitamin D
Erythropoietin
Note: All efforts should be made to inject other injectable medications (ie, insulin, GLP -1 
analogs, erythropoietin) for which the participant has been on a stable regimen in a location 
other than where the study medication/placebo is injected. It is preferred that the MK -2060 
injection site area is not used for other injections for the duration of the study, if possible. 
PROHIBITED MEDICATIONS
Listed below are specific restrictions for concomitant therapy during the course of the study, 
from signing consent to the poststudy visit:
Oral Anticoagulants
Warfarin
Api[INVESTIGATOR_3822]
08V5WQ
PRODUCT: MK-2060 65
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201753] -2023
Dabigatran
Rivaroxaban
Edoxaban
Betrixaban
Antiplatelet Medications
Prasugrel
Ticagrelor
Ticlopi[INVESTIGATOR_861889] (eg, ibuprofen); however, the non- NSAID paracetamol/acetaminophen may be used 
for minor ailments without prior consultation with the Sponsor.
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified for use in this study.
CRUs will be staffed with medically trained personnel with appropriate access to full service 
acute -care hospi[INVESTIGATOR_210631].
6.6 Dose Modification (Escalation/Titration/Other)
The dose and administration of the stu dy intervention to any participant may be modified 
based on newly available safety, tolerability, pharmacokinetic and/or pharmacodynamic data 
observed in this and/or other MK- [ADDRESS_1201754] of this study.
If any of the below stoppi[INVESTIGATOR_26501], the study will be paused, and no further dosing 
will occur until the Sponsor has reviewed the total ity of data available. To continue the study 
(on joint agreement with the Sponsor and investigator), a substantial amendment will be 
submitted for approval.
1.An individual participant reports an SAE considered related to the study intervention by 
[CONTACT_3170].
2.Two (2) or more participants within a Panel (at the same dose level) report Severe 
Nonserious AEs considered related to the study intervention by [CONTACT_093].
3.An increase in local lab aPTT >4.0- fold versus screening baseline as confirmed after
repeat measurement in 2 or more participants in a panel. Local lab aPTT measured at 
Screening Visit should be used as baseline value.
4.An increase in local lab PT >1.5- fold versus screening baseline as confirmed after repeat 
measurement in [ADDRESS_1201755]: MK-2060 66
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201756] -2023
6.7 Intervention After the End of the Study
There is no study -specified intervention after the end of the study.
6.8 Clinical Supplies Disclosure
The emergency unblinding call center will use the intervention randomization schedule for 
the study to unblind participants and to unmask study intervention identity for this study. The 
emergency unblinding call center should only be used in cases of emergency (see Section 
8.1.10). The Sponsor will not provide random code/disclosure envelopes or lists with the 
clinical supplies.
6.[ADDRESS_1201757]: MK-2060 67
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201758] be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study interventi on prior to completion of the protocol- specified treatment 
period regimen will still continue to participate in the study as specified in Section 7.[ADDRESS_1201759] 
occur. In addition, a participant may be discontinued from study intervention by [CONTACT_19419], the study plan is violated, or 
for administrative and/or other safety reasons. Specific details regarding procedures to be 
performed at study intervention discontinuation are provide d in Section 8.1.9.
A participant must be discontinued from study intervention but continue to be monitored in 
the study for any of the following reasons:
•The participant or participant’s legally acceptable representative requests to discontinue 
study inte rvention.
•The participant’s treatment assignment has been unblinded by [CONTACT_093], MSD, or 
through the emergency unblinding call center.
•The participant has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_19348]/or Sponsor, placed the participant at unnecessary risk from continued 
administration of study intervention.
7.[ADDRESS_1201760] be withdrawn from the study if the participant or participant’s legally 
acceptable represent ative withdraws consent from the study.
If a participant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal f rom the 
study, as well as specific details regarding withdrawal from FBR, are outlined in 
Section 8.1.9. The procedures to be performed should a participant repeatedly fail to return 
08V5WQ
PRODUCT: MK-2060 68
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201761] -2023
for scheduled visits and/or if the study site is unable to contact [CONTACT_861900] 7.3.
7.[ADDRESS_1201762] to Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The site must attempt to contact [CONTACT_19423]. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every ef fort to regain contact [CONTACT_19424] (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally equivalent methods). These contact [CONTACT_19425]’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and analysis guideli nes.
08V5WQ
PRODUCT: MK-2060 69
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201763] -2023
8 STUDY ASSESSMENTS AND PROCEDURES
•Study procedures and their timing are summarized in the SoA.
•Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
•The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_19426] (by [CONTACT_8640], training, and experience) staff. Delegation of 
study- site personnel responsibilities will be documented in the Investigator Trial File 
Binder (or equivalent).
•All study- related medical decisions must be made by [CONTACT_19427] a qualified 
physician.
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained b efore signing of ICF may be used for screening or baseline purposes 
provided the procedure s meet the protocol -specified criteria and were performed within 
the time frame defined in the SoA.
•Additional evaluations/testing may be deemed necessary by [CONTACT_861901]. In some cases, such evaluation/testing 
may be potentially sensitive in nature (eg, HIV, hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. In these 
cases, such evaluations/testing will be performed in accordance with those regulations.
•The maximum amount of blood collected from each participant over the duration of Part 
1will not exceed ~294.8 mL , over Part 2 will not exceed ~428.3 mL, and over Part 3 will 
not excee d ~320.2 mL (Appendix 8 and operations/laboratory manual ).
•Repeat or unscheduled samples may be taken for safety reasons or for technical issues 
with the samples.
8.1 Administrative and General Procedures
8.1.1 Inform ed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent from each potential participant (or their legally 
acceptable representative) prior to participating in this clinical st udyor FBR . If there are 
changes to the participant’s status during the study (eg, health or age of majority 
requirements), the investigator or medically qualified designee must ensure the appropriate 
documented informed consent is in place.
08V5WQ
PRODUCT: MK-2060 70
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201764] -2023
[IP_ADDRESS] General Inform ed Consent
Informed consent given by [CONTACT_19429] a consent form. The form must include the study protocol number, study 
protocol title, dated signature, and agreement of the participant (or his/her legally acceptable 
representative) and of the person conducting the consent discussion.
A copy of the signed and dated informed consent form should be given to the participant (or 
their legally acceptable representative) before participation in the study.
The initial ICF, any subsequent revised ICF, and any written information provided to the 
participant must receive the IRB/IEC’s approval/favorable opi[INVESTIGATOR_19349]. The 
participant or his/her lega lly acceptable representative should be informed in a timely manner 
if new information becomes available that may be relevant to the participant’s willingness to 
continue participation in the study. The communication of this information will be provided 
and documented via a revised consent form or addendum to the original consent form that 
captures the participant’s or the participant’s legally acceptable representative’s dated 
signature.
If the investigator recommends continuation of study intervention beyond disease 
progression, the participant or their legally acceptable representative will be asked to provide 
documented informed consent.
Specifics about the study and the study population are to be included in the study informed 
consent form.
Informed con sent will adhere to IRB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements.
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically qualified designee will explain the FBR consent to the 
participant, or the participant’s legally acceptable representative, answer all of his/her 
questions, and obtain documented informed consent before performing any procedure related 
to FBR. A copy of the informed consent will be given to the participant before performing 
any procedure related to FBR.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093], who is a qualified 
physician, to ensure that the participant qualifies for the study.
8.1.[ADDRESS_1201765] information (including direct 
telephone numbers) to be used in the event of an emergency . The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
08V5WQ
PRODUCT: MK-2060 71
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201766] -2023
the participant provides documented informed consent. At the time of intervention
randomization, site personnel will add the trea tment/randomization number to the participant 
identification card.
The participant identification card also contains contact [CONTACT_19430] a health care provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4 Medical History
A medical history will be obtained by [CONTACT_27404].
8.1.5 Prior and Concomitant Medications Review
[IP_ADDRESS] Prior Medications
The investigator or qualified designe e will review before medication use, including any 
protocol -specified washout requirement, and record prior medication taken by [CONTACT_88688] 28 days before starting the study.
[IP_ADDRESS] Concomitant Medications
The investigator or qualified designee will re cord medication, if any, taken by [CONTACT_19432]. Refer to Section 6.[ADDRESS_1201767] not be reused f or 
different participants.
8.1.7 Assignment of Treatment/Randomization Number
For Parts 1 and 2, a lleligible participants will be randomly allocated and will receive a 
treatment/randomization number. For Part 3 ,all eligible participants will be allocated, by 
[CONTACT_148195], and will receive a t reatment/allocation number. The
treatment/randomization /allocation number identifies the participant for all procedures 
occurring after treatment randomization/allocation .Once a 
treatment/randomization /allocation number is assigned to a participant, it ca n never be 
reassigned to another participant.
A single participant cannot be assigned more than 1 treatment/randomization /allocation
number.
08V5WQ
PRODUCT: MK-2060 72
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201768] -2023
8.1.8 Study Intervention Administration
Administration of study medication will be witnessed by [CONTACT_1755]/or s tudy staff 
according to the specifications within the Study Pharmacy Manual.
[IP_ADDRESS] Timing of Dose Administration
MK-2060/placebo will be prepared and dosed per the instructions outlined in the Study 
Pharmacy Manual. All doses of MK -[ADDRESS_1201769] -dose except to stand 
for the measurement of orthostatic VS (if needed) or other study procedures (for example for 
breakfast).
8.1.[ADDRESS_1201770] notify the Sponsor when a parti cipant has been 
discontinued/withdrawn from the study. If a participant discontinues for any reason at any 
time during the course of the study, the participant may be asked to return to the clinic (or be 
contact[INVESTIGATOR_530]) for a poststudy visit as per the number of days described in Section 1.3 (90 days
for Part 1, 1 30days for Part 2, and 120 days for Part 3 )to have the applicable procedures 
conducted. However, the investigator may decide to perform the poststudy procedures at the 
time of discontinuation or as soon as possible after discontinuation. If the poststudy visit 
occurs prior to the safety follow -up time frame as specified in Section 8.4.1 , the investigator 
should perform a follow -up telephone call at the end of the follow -up period ( Section 8.4.1) 
to confirm if any AEs have occurred since the poststudy clinic visit. Any AEs that are present 
at the time of discontinuation/withdrawal should be fo llowed in accordance with the safety 
requirements outlined in Section 8.4.
[IP_ADDRESS] Withdrawal From Future Biomedical Research
Participants may withdraw their consent for FBR. Participants may withdraw consent at any 
time by [CONTACT_88690]. If me dical records for the study are still available, 
the investigator will contact [CONTACT_75355] 
([EMAIL_2453]). Subsequently, the participant’s consent for 
FBR will be withdrawn. A letter will be sent from the Sponsor to the investigator confirming 
the withdrawal. It is the responsibility of the investigator to inform the participant of 
completion of withdrawal. Any analyses in progress at the time of request for withdrawal or 
already performed before the requ est being received by [CONTACT_88691]. No new analyses would be generated 
after the request is received.
If the medical records for the study are no longer available (eg, if the in vestigator is no longer 
required by [CONTACT_88692]) or the specimens have been 
completely anonymized, there will no longer be a link between the participant’s personal 
information and their specimens. In this situation, the request for specimen withdrawal 
cannot be processed.
08V5WQ
PRODUCT: MK-2060 73
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201771] -2023
8.1.10 Participant Blinding/Unblinding
STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For e mergency situations where the investigator or medically qualified designee (consistent 
with local requirements) needs to identify the intervention used by a participant and/or the 
dosage administered, he/she will contact [CONTACT_861902] r by [CONTACT_311660] a request for emergency unblinding. As requested by [CONTACT_19445], the emergency unblinding call center will provide the information to 
him/her promptly and report unblinding to the Sponsor. Before contact[CONTACT_88694] a participant’s intervention assignment, the 
investigator who is qualified physician should make reasonable attempts to enter the intensity 
of the AEs observed, the relation to study intervention, the reason thereof, etc, in the medical 
record. If it is not possible to record this assessment in the medical record before the 
unblinding, the unblinding should not be delayed.
If unblinding has occurred, the circumstances around the unbli nding (eg, date, reason, and 
person performing the unblinding) must be documented promptly, and the Sponsor Clinical 
Director notified as soon as possible.
Once an emergency unblinding has taken place, the investigator, site personnel, and Sponsor 
personne l may be unblinded so that the appropriate follow -up medical care can be provided 
to the participant.
Participants whose treatment assignment has been unblinded by [CONTACT_93311]/or nonstudy treating physician must be discontinued from study 
intervention, but should continue to be monitored in the study.
8.1.[ADDRESS_1201772] 48- hours postdose. For Part 2 participants will report to the CRU the 
evening before the scheduled day of study intervention administration on Day 1 and will 
remain in the unit until the completion of off all postdose procedures on Day 4 (at least 4 
hours). For the remaining dosing days in Part 2, at the discretion of the investigator the 
participants will return to the CRU either the evening before the scheduled day of study 
intervention administration or the morning of the scheduled day of study intervention 
administration (Days 8, 15 and 22) and will remain in the unit overnight until the completion 
of all postdose procedures the following day (at least 4 hours). At the discretion of the 
investigator, participants may be requested to remain in the CRU longer.
8.1.12 Calibration of Equipment
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinical study that provides information 
08V5WQ
PRODUCT: MK-2060 74
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201773] -2023
about inclusion/exclusion criteria and/or safety or efficacy paramet ers shall be suitably 
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study site.
8.2 Efficacy/Immunogenicity Assessments
There are no direct efficacy/immunogenicity assessments in this study.
8.3 Safety Assessments
Details regarding specific safety procedures/assessments to be performed in this study are 
provided. The total amount of blood to be drawn over the course of the study ( from pre -study 
to poststudy visits), including approximate blood volumes drawn by [CONTACT_123668], can be found in Appendix 8.
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete physical examination will be conducted by [CONTACT_88696] (consistent with local requirements) per institutional standard as per the SoA. A 
symptom driven physical exam will be conducted based upon any emergent symptoms at the 
discretion of the investigator. Height and weight will also be measured and recorded.
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
Targeted physical examination will involve a skin exam to assess f or any unusual bruising or 
bleeding under the skin.
[IP_ADDRESS] Body Weight and Height
Body weight and height will be obtained with the participant’s shoes off and jacket or coat 
removed.
[IP_ADDRESS] Body Mass Index (BMI)
BMI equals a person's weight in kilograms divided by [CONTACT_282132] t in meters squared 
(BMI=kg/m2). BMI will be rounded to the nearest whole number according to the standard 
convention of 0.1 to 0.4 round down and 0.5 to 0.9 round up.
8.3.2 Vital Signs
•Body temperature, HR, RR, and BP will be assessed.
•BP and pulse measurements will be assessed semi -recumbent after at least [ADDRESS_1201774]: MK-2060 75
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201775] -2023
[IP_ADDRESS] Resting Vital Signs
Vital Sign Measurements (Heart Rate and Blood P ressure)
Participants should be resting in a quiet setting without distractions in a semi -recumbent 
position for at least [ADDRESS_1201776] positioning on the 
participant’s arm is essential to increase the accuracy of BP measurements.
For Parts 1, 2, and 3, t he Day 1 predose (baseline) HR and BP will be in triplicate 
measurements, obtained at least 1 to 2 minutes apart within 3 hours of dosing of study 
intervention. The median of these measurements will be used as the baseline to calculate 
change from baseline for safety evaluations (and for rechecks, if needed). Post -dose VS 
measurements will be single measurements.
Participants will continue to rest semi -recumbent from dosing until [ADDRESS_1201777] -dose except 
to stand for the measurement of orthostatic VS (if needed) or other study -related procedure.
Body T emperature
Body temperature will be a single measurement at all timepoints. The same method must be 
used for all measurements for each individual participant and should be the same for all 
participants.
Respi[INVESTIGATOR_861164] (breaths per minute) will be measured and recorded as single measurements.
[IP_ADDRESS] Orthostatic Vital Signs
Orthostatic VS (HR and systolic and diastolic BP) will also be obtained. Participants should 
be semi -recumbent for at least 10 minutes and then stand upright for approximately 
2minutes before measurement of orthostatic VS.
8.3.3 Electrocardiograms
•Triplicate and single 12 -lead ECG will be obtained and reviewed by [CONTACT_306171] (consistent with local requirements) as outlined in the SoA 
using an ECG m achine that automatically calculates the HR and measures PR, QRS, QT, 
and QTc intervals. 
•At each time point when triplicate ECG are required, [ADDRESS_1201778]: MK-2060 76
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201779] 10 minutes before each ECG 
measurement.
The QTc correction formula to be used at the site (for safety and inclusion/exclusion criteria 
assessments) is Fridericia.
If repeat ECGs are required, the clinical site will decide whether to leave the electrodes in 
place or mark the position of the electrodes for subsequent ECGs. To mark the position of the 
electrodes, [ADDRESS_1201780] 1 to 2 
minutes apart (and should be completed in no more than 6 minutes) within 3hours prior to 
dosing MK -2060. The median of these measurements will be used as the baseline to calculate 
change from baseline for safety evaluations (and for rechecks, if needed). Unless otherwise 
designated in the flow chart, post -dose ECG measurements will be single measurements.
If a participant demonstrates an increase in QTc interval ≥[ADDRESS_1201781] -dose time point i s ≥[ADDRESS_1201782] 1 hour or until the QTc is within 60 msec of baseline. If prolongation of the QTc 
interval ≥[ADDRESS_1201783] may be appropriate and 
the Sponsor should be notified.
If the median QTc interval is ≥[ADDRESS_1201784]. The participant should be telemetry monitored (until 
the QTc is <500 ms ec) or should be considered for transfer to a location where closer 
monitoring and definitive care (eg, a CCU or ICU) is available.
If the participant has unstable hemodynamics, or has any clinically significant dysrhythmias 
noted on telemetry, the partici pant should be immediately transferred to an acute care setting 
for definitive therapy.
If prolongation of the QTc is noted, concomitant medications that prolong QTc should be 
held until the QTc is within 60 msec of baseline and the QTc is <[ADDRESS_1201785]: MK-2060 77
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201786] -2023
8.3.4 24-Hour Urine Protein, 24 -Hour Urine Creatinine and Spot Urine Collection 
for Urine Protein: Urine Creatinine Ratio (uPCR)
A 24 -hour urine protein will be collected. The collection will begin following admission to 
the CRU on the evening before study intervention dosing on Day 1 and continue through to 
the evening of Day 1.
Spot urine for uPCR will be collected on study days as defined in the study flowchart (SoA).
8.3.[ADDRESS_1201787] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
•The investigator or medically qualified designee (consistent with local requirements) 
must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the CRF. The laboratory 
reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless 
judged by [CONTACT_19448]’s condition.
•All protocol -required laboratory asses sments, as defined in Appendix [ADDRESS_1201788] be 
conducted in accordance with the laboratory manual and the SoA .
•If laboratory values from nonprotocol -specified laboratory assessments performed at the 
institution’s local laboratory require a change in study parti cipant management or are 
considered clinically significant by [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
•For any laboratory tests with values considered clinically significantly abnormal during 
participation In the study or within 90days after the last dose of study intervention, every 
attempt should be made to perform repeat assessments until the values ret urn to normal or 
baseline or if a new baseline is established as determined by [CONTACT_093] .
8.3.[ADDRESS_1201789]: MK-2060 78
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201790] 30 to 60 minutes of 
administration, though they may be observed up to 24 to 30 hours postdose. An anaphylactic 
reaction is a severe type of injection reaction that is characterized by [CONTACT_861903], such as generalized hives, pruritus or flushing, swollen lips -tongue -uvula and 
angioedema, accompanied by [CONTACT_15206][INVESTIGATOR_7798] (bronchospasm, stridor or hoarseness) 
and/or changes in blood pressure (hypotension). Severe injection reactions, including 
cytokine release syndrome and hypersensitivity reactions must be promptly treated with 
interruption of the injection, medical management, appropriate monitoring, and life -saving 
measure s. Appropriate resuscitation equipment and a physician should be readily available 
during the period of drug administration. 
All participants should be evaluated for injection -type reactions. Participants should be 
carefully observed until complete resolution of all signs and symptoms, if a reaction occurs. 
Report any adverse experiences according to the guidelines in Section 8.4.
[IP_ADDRESS] Systemic Injection Reaction Assessment
Participants will be monitored during the administration of MK -2060/placebo and for at l east 
4 hours and up to 24 to 48 hours postdose at the CRU after the initiation of administration. 
During this time, signs and symptoms of a systemic injection reaction, including but not 
limited to fever, VS changes (tachycardia/hypotension), pruritis, urticarial (hives), lip 
swelling, angioedema, bronchospasm, stridor, hoarseness, and shortness of breath will be 
monitored. Injection reactions must be assessed and managed promptly. Such assessment and 
management are discussed in Section 8.3.7.
[IP_ADDRESS] Local Injection Reaction Assessment
A local injection site examination will be obtained as outlined in the Section 1.3 and will 
include an assessment of any pain, tenderness, erythema/redness and induration/swelling. 
These events will be evaluated based upon the system outlined in the guidance for the 
industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in 
Preventive Vaccine Clinical Trials inTable [ADDRESS_1201791] be assessed and 
managed promptly per site procedure. 
Participants who call the CRU to report an infusion/injection site reaction within [ADDRESS_1201792]: MK-2060 79
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201793] -2023
Table 5 Local Injection Reaction Assessment
Local Site 
ReactionMild Moderate Severe Potentially Life 
Threatening
Pain Does not interfere 
with activityRepeated use of 
non-narcotic pain 
reliever >24 hr or 
interferes with 
activityAny use of 
narcotic pain 
reliever or prevents 
daily activityEmergency room 
(ER) visit or 
hospi[INVESTIGATOR_861890]/Redness 2.5 –5 cm 5.1 –10 cm >10 cm Necrosis or 
exfoliative 
dermatitis
Induration/Swelling 2.5 –5 cm and 
does not interfere 
with activity5.1 –10 cm or 
interferes with 
activity>10 cm or prevents 
daily activityNecrosis
Adapted from the guidance for the industry Toxicity Grading Scale for Healthy Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials.
8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3 .
Adverse events, SAEs, and other reportable safety events will be reported by [CONTACT_2299] 
(or, when appropriate, by a caregiver, surrogate, or the participant ’s legally authorized 
representative).
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safety events. 
Investigators need to document if an SAE was associated with a medication error, misuse, or 
abuse.
Investigators remain responsible for following up AEs, SAEs, and other reportable safety 
events for outcome according to Section 8.4.3. The investigator, who is a qualified physician, 
will assess events that meet the definition of an AE or SAE as we ll as other reportable safety 
events with respect to seriousness, intensity/toxicity ,and causality.
08V5WQ
PRODUCT: MK-2060 80
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201794] be reported by 
[CONTACT_123672]:
•if the participant is receiving placebo run- in or other run -in treatment,
•if the event causes the participant to be excluded from the study,
•if it is the result of a protocol -specified intervention, including, but not limited to washout 
or discontinuation of usual therapy, die t, placebo, or a procedure.
From the time of intervention randomization through ~[ADDRESS_1201795] promptly notify the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety events will be recorded and 
reported to the Spons or or designee within the time frames as indicated in Table 6.
Exception: A positive pregnancy test at the time of initial screening is not a reportable event 
unless the participant has received study intervention.
08V5WQ
PRODUCT: MK-2060 81
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201796] -2023
Table 6 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safety Events
Type of EventReporting Period:
Consent to 
Randomization/
AllocationReporting Period:
Randomization/
Allocation 
through Protocol -
specified Follow -
up PeriodReporting 
Period:
After the 
Protocol -
specified Follow -
up PeriodTime Frame to 
Report Event 
and Follow- up 
Information to 
Sponsor
NSAE Report if:
–due to protocol -
specified 
intervention
–causes exclusion
–participant is 
receiving placebo 
run-in or other run -
in treatmentReport all Not required Per data entry 
guidelines
SAE Report if:
–due to protocol -
specified 
intervention
–causes exclusion
–participant is 
receiving placebo 
run-in or other run -
in treatmentReport all Report if:
–drug/vaccine 
related.
(Follow 
ongoing to 
outcome)Within 
24hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if:
–participant has been 
exposed to any 
protocol -specified 
intervention (eg, 
procedure, washout ,
or run -in treatment 
including placebo 
run-in)
Exception: A positive 
pregnancy test at the 
time of initial 
screening is not a 
reportable event.Report all Previously 
reported – Follow 
to completion/
termination; 
report outcomeWithin 
24hours of 
learning of 
event
ECI (require 
regulatory reporting)Report if:
–due to intervention
–causes exclusionReport
–potential DILI
–require regulatory 
reportingNot required Within 
24hours of 
learning of 
event
ECI (do not require 
regulatory reporting)Report if:
–due to intervention
–causes exclusionReport
–non-DILI ECIs 
and those not 
requiring 
regulatory 
reportingNot required Within 
5calendar days 
of learning of 
event
08V5WQ
PRODUCT: MK-2060 82
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201797] -2023
Type of EventReporting Period:
Consent to 
Randomization/
AllocationReporting Period:
Randomization/
Allocation 
through Protocol -
specified Follow -
up PeriodReporting 
Period:
After the 
Protocol -
specified Follow -
up PeriodTime Frame to 
Report Event 
and Follow- up 
Information to 
Sponsor
Cancer Report if:
–due to intervention
–causes exclusionReport all Not required Within 
5calendar days 
of learning of 
event (unless 
serious)
Overdose Report if:
–receiving placebo 
run-in or other run -
in medication Report all Not required Within 
24hours of 
learning of 
event
DILI=drug -induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; SAE=serious 
adverse even t.
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AEs and/or SAEs and other 
reportable safety events. Open- ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information
After the initial AE /SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AEs, SAEs, and other reportable safety events, 
including pregnancy and exposure during breastfeeding, ECIs, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3). In addition, the investigator will 
make every attempt to follow all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt no tification (within 24 hours ) by [CONTACT_113809] a study intervention under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply with country- specific regulatory requirements and gl obal laws and 
regulations relating to safety reporting to regulatory authorities, IRB/IECs, and investigators.
Investigator safety reports must be prepared for S[LOCATION_003]Rs according to local regulatory 
requirements and Sponsor policy and forwarded to investigat ors as necessary.
08V5WQ
PRODUCT: MK-2060 83
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201798] -2023
An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAE s) from the Sponsor will file it 
along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the study are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy.
Any pregnancy complication will be reported as an AE or SAE.
The m edical reason (example: maternal health or fetal disease) for an elective termination of 
a pregnancy will be reported as an AE or SAE. Prenatal testing showing fetus will be born 
with severe abnormalities/congenital anomalies that leads to an elective term ination of a 
pregnancy will be reported as an SAE for the fetus.
Pregnancy outcomes of ectopic pregnancy, spontaneous abortion, missed abortion, benign 
hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth 
must be r eported as serious events (Important Medical Events). If the pregnancy continues to 
term, the outcome (health of infant) must also be reported.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Not applicable.
8.4.[ADDRESS_1201799] for this study include:
1.An overdose of Sponsor ’s product, as defined in Section 8.5.
2.Potential DILI events defined as an elevated AST or ALT laboratory value that is greater 
than or equal to 3 ×the ULN and an elevated total bilirubin laboratory value that is greater 
than or equal to 2 ×the ULN and, at the same time, an alkaline phosphatase laboratory 
value that is less than 2× the ULN, as determined by [CONTACT_13149] -specified laboratory 
testing or unscheduled laboratory testing.*
*Note: These criteria are based on available regulatory guidance documents. The purpose 
of the criteria is to specify a threshold of abnormal hepatic tests that may require an 
additional evaluation for an underlying etiology. The study -site guidance for assessment 
and follow -up of these criteria can be found in the Investigator Study File Binder (or 
equivalent).
08V5WQ
PRODUCT: MK-2060 84
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201800], ALT, bilirubin, and alkaline 
phosphatase that do not meet the criteria noted above. In these cases, th e decision to proceed 
with additional evaluation will be made through consultation between the study investigators 
and the Sponsor Clinical Director. However, abnormalities of liver blood tests that do not 
meet the criteria noted above are not ECIs for thi s study.
8.5 Treatment of Overdose
For purposes of this study, an overdose will be defined as any dose of any drug administered 
as part of the study exceeding the dose prescribed by [CONTACT_760]. It is up to the investigator 
or the reporting physician to decid e whether a dose is to be considered an overdose, in 
consultation with the Sponsor.
Sponsor does not recommend specific treatment for an overdose. Decisions regarding dose 
interruptions or modifications will be made by [CONTACT_508231].
8.6 Pharmacokinetics
The decision as to which plasma and/or urine samples collected will be measured for 
evaluation of PK/pharmacodynamics will be collaboratively determined by [CONTACT_1034] (eg, 
samples at lower doses may not be measured if samples at higher doses reveal undetectable 
drug concentrations). If indicated, these samples may also be measured and/or pooled for 
assay in an exploratory manner for metabolites and/or addit ional pharmacodynamic markers. 
Blood samples collected may be stored and further analysis may be performed, if required.
8.6.[ADDRESS_1201801]: MK-2060 85
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201802] -2023
8.7.2 Blood for Plasma ADA
Sample collection, storage, and shipment instructions for plasma samples will be provided in 
a separate Study Operations Manual by [CONTACT_1034].
8.8 Biomarkers
Collection of samples for other biomarker research is also part of this study. The following 
samples for biomarker research are required and will be collected from all participants as 
specified in the SoA.
•Blood for genetic analysis
8.8.1 Planned Genetic Analys is Sample Collection
The planned genetic analysis sample should be drawn for planned analysis of the association 
between genetic variants in DNA and drug response. This sample will not be collected at the 
site if there is either a local law or regulation p rohibiting collection, or if the IRB/IEC does 
not approve the collection of the sample for these purposes. If the sample is collected, 
leftover extracted DNA will be stored for FBR if the participant provides documented 
informed consent for FBR. If the pla nned genetic analysis is not approved, but FBR is 
approved and consent is given, this sample will be collected for the purpose of FBR.
Sample collection, storage, and shipment instructions for planned genetic analysis samples 
will be in the Operations/Laboratory Manual.
8.9 Future Biomedical Research Sample Collection
If the participant provides documented informed consent for FBR, the following specimens 
will be obtained as part of FBR:
•Leftover samples from Section 8.8.
8.[ADDRESS_1201803]: MK-2060 86
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201804] -2023
Participants may be rescreened after consultation with the Sponsor. Rescreening should 
include all screeni ng procedures listed in the SoA, including consent review. Rescreen 
procedures cannot be conducted the day prior to intervention randomization if there are 
Day -1 procedures planned per protocol .
8.11.2 Treatment Period
Refer to the Schedule of Activities (Sectio n 1.3) and Administrative and General Procedures 
(Section 8.1).
After all predose procedures have been completed and it is confirmed that the participant 
meets eligibility; the participant will be given a participant ID bracelet and assigned a unique 
rando mization number associated with a specific treatment as defined by a computer -
generated randomization schedule. Participants will report to the CRU prior to the scheduled 
day of dosing or time specified by [CONTACT_093]. On the day of dosing, participan ts will 
fast from all food and drinks, except water, for at least [ADDRESS_1201805] (see Section 5.3.1). 
Participants will be administered study intervention as indicated in Section 6. Participants 
who, on Day 1, have a significant acute illness or fever prior to the administration of study 
drug may be rescheduled.
8.11.[ADDRESS_1201806] dose of study intervention for the poststudy visit. 
If the poststudy visit occurs fewer than 90 /130/[ADDRESS_1201807] dose of study 
intervention, a subsequent follow -up telephone call should be made at 90/1 30/[ADDRESS_1201808] -study visit may 
continue to be monitored in the study per the visit requirements in the SoA.
8.11.5 Safety Phone Call Follow -Up
A safety follow- up phone call will be performed approximately 14 days after the poststudy 
visit (within the visit windows allowed per protocol). The safety follow -up phone call must 
be performed by [CONTACT_474518]. At the discretion of the investigator an 
in-person follow -up may be performed. If the initial call is unsuccessful, the study site should 
08V5WQ
PRODUCT: MK-2060 87
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201809] be documented in the source documents.
8.11.6 Critical Procedures Based on Study Objectives: Timing of Procedure
For this study, the blood sample for MK -[ADDRESS_1201810] time point as possible. All other procedures should be completed as close to the 
prescribed/scheduled time as possible. Study procedures can be performed before or after the 
prescribed/scheduled time.
The order of priority can be changed during the study with joint agreement of the investigator 
andthe Sponsor Clinical Director.
Any nonscheduled procedures required for urgent evaluation of safety concerns take 
precedence over all routine scheduled procedures.
The following variance in procedure collection times will be permitted.
•Screening 2 procedu res: up to additional 4 hours of scheduled time 
•PK, Pharmacodynamic and Safety Collection as outlined in Table 7, Table 8, and Table 
9.
Table 7 Pharmacokinetic, Pharmacodynamic and Safety (Blood/Urine) Collecti on 
Window sfor Part1
Pharmacokinetic, 
Pharmacodynamic , Safety
CollectionPharmacokinetic, Pharmacodynamic , 
Safety Collection Window
0 to < 4 hours 5 min
4 -< 8 h ours 15 min
8 - < 24 hours 30 min
24 hours - < 48 h ours 60 min
48 hours -< 120hours 2 hours
120hours -≤ 168hours 24 hours
Day 11 + Day 14 1 Day
Day 21 2 Days
Day 28 3 Days
Day 60 + Day [ADDRESS_1201811]: MK-2060 88
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201812] -2023
Table 8 Pharmacokinetic, Pharmacodynamic and Safety (Blood/Urine) Collection 
Windows for Part 2
Pharmacokinetic, 
Pharmacodynamic , Safety
CollectionPharmacokinetic, Pharmacodynamic , 
Safety Collection Window
0 to < 4 hours 5 min
Days 1, 2, 3, 4, 8, 15, 22, 23, and 
29No flexible window for the scheduled 
day
Days 10 and 17 ±1 Day
Day 26 +1 Day
Days 35, 42, 49 and 63 ±2 Days
Days 81 and 111 ±3Days
Day 130 ±7 Days
Table 9 Pharmacokinetic, Pharmacodynamic and Safety (Blood/Urine) Collection 
Windows for Part 3
Pharmacokinetic, 
Pharmacodynamic , Safety
CollectionPharmacokinetic, Pharmacodynamic , 
Safety Collection Window
0 to < 4 hours 5 min
4 -< 8 h ours 15 min
8 - < 24 hours 30 min
24 hours - < 48 h ours 60 min
48 hours -< 120hours 2 hours
120hours -≤ 168hours 24 hours
Day 11 + Day 14 1 Day
Day 21 2 Days
Day 28 3 Days
Day 60 + Day 90 + Day [ADDRESS_1201813]: MK-2060 89
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201814] -2023
•Part 1, 2, and [ADDRESS_1201815] safety evaluations: VS and ECG at 3 hours; 
laboratory safety tests and physical exam at 24 hours
•Part [ADDRESS_1201816] safety evaluations: VS, ECG, and laboratory 
safety tests at 3 hours.
•Post-dose standard safety evaluations: VS, ECG, laboratory safety tests, and physical 
exam
-Prior to 24- hours postdose may be obtained within 15 minutes of the theoretical 
sampling time
- Between 24- hours and <48-hours postdose may be obtained within 1 hour of the 
theoretical sampling time
-From 48 -hours to <1 20-hours postdose may be obtained within 2 hours of the 
theoretical sampling time
Note: Visit windows defined by +/ -X day(s) refers to calendar days.
8.11.7 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
This is a Phase 1 assessment of MK- 2060 in humans, and the PK, pharmacodynamic, and 
safety profiles of the compound are still being elucidated. This protoco l is written with some 
flexibility to accommodate the inherent dynamic nature of Phase 1 clinical studies. 
Modifications to the dose, dosing regimen, and/or clinical or laboratory procedures currently 
outlined may be required to achieve the scientific goal s of the study objectives and/or to 
ensure appropriate safety monitoring of the study participants.
As such, some alterations from the currently outlined dose and/or dosing regimen may be 
permitted based on newly available data, but the maximum daily dose may not exceed those 
currently outlined in the protocol.
•Repeat of or decrease in the dose of the study intervention administered in any given 
period/panel /part
•Addition of study pause
•Instructions to take study intervention with or without food or drink m ay also be modified 
based on newly available data
•Modification of the PK/pharmacodynamic sample processing and shippi[INVESTIGATOR_508216]/pharmacodynamic sampling scheme currently outlined in the protocol may be 
modified during the study based on newly available PK or pharmacodynamic data (e.g., to 
obtain data closer to the time of peak plasma concentrations). If indicated, these collected 
samples may also be assayed in an exploratory manner for metabolites and/or additional 
pharmacodynamic markers.
08V5WQ
PRODUCT: MK-2060 90
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201817] -2023
Up to additional 50 mL of blood may be drawn for safety, PK, and/or pharmacodynamic 
analyses. The total blood volume withdrawn from any single participant will not exceed the 
maximum allowable volume during his/her participation in the entire study (Appendix 8).
The timing of procedures for assessment of safety procedures (eg, VS, ECG, safety 
laboratory tests, etc.) may be modified during the study based on newly available data. 
Additional laboratory safety tests may be added to blood s amples previously drawn to obtain 
additional safety information. These changes will not increase the number of study 
procedures for a given participant during his/her participation in the entire study.
It is understood that the current study may use some o r none of the alterations described 
above. Any alteration made to this protocol to meet the study objectives must be detailed by 
[CONTACT_21411] a letter to the Study File and forwarded to the investigator for retention. The 
letter may be forwarded to the I RB/IEC at the discretion of the investigator.
08V5WQ
PRODUCT: MK-2060 91
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201818] -2023
9 STATISTICA L ANALYSIS PLAN
9.1 Statistical Analysis Plan Summary
This section contains a brief summary of the statistical analyses for this study. Full details 
can be found in the subsequent sections.
Safety
Summary statistics and plots will be generated for raw laboratory safety tests, ECGs, and/or 
VS as well as for change from baseline, as deemed clinically appropriate. Depending on the 
safety parameter, the difference from baseline will either be computed on the original scale 
(raw change from baseline) or on the log scale and back -transformed for reporting (percent 
change from baseline).
9.[ADDRESS_1201819] auspi[INVESTIGATOR_26338], the Early Clinical Development Statistics Department in collaboration 
with the Quantitative Pharmacology and Pharmacometrics Department and Translational 
Pharmacology Department of the Sponsor.
If, after the study has begun, changes are made to the statistical analysis plan stated below, 
then these deviations to the plan will be listed, along with an explanation as to why they 
occurred, in the Clinical Study Report.
9.3 Hypotheses/Estimation
Objectives of the study are stated in Section 3.
9.4 Analysis Endpoints
Primary Endpoints
1.Primary endpoints are bleeding related AEs, AEs , and discontinuations due to AEs.
•Pharmacokinetics: The pharmacokinetic variables of primary interest for MK -2060 are 
measurement of MK- 2060 plasma AUC0- ∞, AUC0 -168, Cm ax, C168, Tmax, terminal 
t1/2, CL/F and Vz/F
Part 1 Hypothesis:
The true geometric mean AUC0- ∞ is at least [ZIP_CODE] nM*hr. This value is based on the 
preliminary modeling and simulation analyses using data form MK -[ADDRESS_1201820]: MK-2060 92
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201821] -2023
Secondary Endpoi nts
2.Pharmacodynamics: The pharmacodynamics variable of secondary interest is fold- change 
in baseline in aPTT values. Baseline is defined as the predose value.
Exploratory Endpoints:
Pharmacodynamics: The pharmacodynamics variables of exploratory interest are Factor XI 
activity levels and prothrombin time.
9.5 Analysis Populations
The following populations are defined for the analysis and reporting of data. All participants 
will be reported, and their data analyzed, according to the treatment(s) they actually r eceived.
All Participants as Treated: The All Participants as Treated Population consists of all 
participants who received at least one dose of treatment.  This population will be used for 
assessments of safety and tolerability.
Per-Protocol (PP): The Per -Protocol Population consists of the set of data generated by [CONTACT_861904], according to the underlying scientific model. 
Compliance covers such considerations as exposure to treatment, availability of 
measurements and absence of important protocol deviations.  Important protocol deviations 
will be identified to the extent possible prior to unblinding by [CONTACT_100935]/compliance, and its analysis and interpretation.  Any participants or data values 
excluded from analysis will be identified, along with their reason for exclusion, in the CSR.  
At the end of the study, all participants who are complian t with the study procedure as 
aforementioned and have available data from at least one treatment will be included in the 
Per-Protocol dataset.
9.6 Statistical Methods
Summary statistics and plots will be generated for raw laboratory safety tests, ECGs, and/or 
VS as well as for change from baseline, as deemed clinically appropriate.  For all endpoints 
descriptive summary will be provided. For categorical measurements, counts and percentage 
numbers will be provided. Similarly, for continuous measurements, mean, standard 
deviation, median, min, max will be provided. Depending on the safety parameter, the 
difference from baseline will either be computed on the original scale (raw change from 
baseline) or on the log scale and back -transformed for reporting (pe rcent change from 
baseline) as appropriate. Values will be listed for each PK parameter (including Tmax and 
apparent terminal t1/2), and appropriate non -model based descriptive statistics will be 
provided: N (number of participants with non -missing data), arithmetic mean, standard 
deviation, arithmetic percent CV (calculated as 100*sqrt(exp(s2) -1), where s2 is the observed 
variance on the natural log- scale.)
08V5WQ
PRODUCT: MK-2060 93
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201822] the part 1 primary hypothesis, the posterior probability that the true geometric mean 
of AUC0 -∞ after a single well -tolerated dose of MK -[ADDRESS_1201823] [ZIP_CODE] nM*hr, will be calculated using a noninformative prior. The CV for AUC0 -∞ 
is expected to be approximately 30% (assuming similar variability as in MK -2060 P004).  If 
this posterior prob ability exceeds 60%, then the primary research hypothesis will be 
supported.
Since Part 2 and Part 3 involve sestimation, descriptive statistics (mean, median, standard 
deviation, min, max values) will be provided for primary and secondary endpoints.
9.7 Inter im Analyses
No interim analysis is planned for this study.
9.8 Multiplicity
Since there is a single prespecified primary hypotheses, no adjustments for multiplicity are 
needed.
9.9 Sample Size and Power Calculations
For Part 1, a pproximately 12 participants will be enrolled for this study. Participants will be 
randomized in a 3:1 ratio to receive a single 30- mg SC dose of MK -2060 (n=9) or placebo 
(n=3). 
Thus, with all 9 participants in MK -2060 group completing the study and a pos terior 
probability threshold of 60%, there is approximately 82% probability of supporting the 
primary hypothesis if the true geometric mean of AUC0 -∞ is [ZIP_CODE] assuming CV=30% and 
natural log- normal distribution for AUC0- ∞. We assume that at 30- mg dose SC dose, the true 
GM is [ZIP_CODE]. A table with PP calculations with assumptions about various values of the true 
GM and with CV=30% is as follows:
True Geometric Mean Probability of Go (%)
[ZIP_CODE] 75.6%
[ZIP_CODE] 77.9%
[ZIP_CODE] 80.3%
[ZIP_CODE] 82.4%
[ZIP_CODE] 84.4%
[ZIP_CODE] 86.2%
08V5WQ
PRODUCT: MK-2060 94
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201824] -2023
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_1201825] for Interventional Clinical Trials
[COMPANY_006] Sharp & Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD)
I.Introduction
A.Purpose
[COMPANY_006] Sharp & Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD), through its subsidiaries, 
conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, planning, conduc ting, analyzing, 
and reporting these trials in compliance with the highest ethical and scientific 
standards. Protection of participants in clinical trials is the overriding concern in the 
design and conduct of clinical trials. In all cases, MSD clinical tr ials will be 
conducted in compliance with MSD’s global standards, local and/or national 
regulations (including all applicable data protection laws and regulations), and 
International Council for Harmonisation Good Clinical Practice (ICH GCP) E6 and 
ICH Gen eral Considerations for Clinical Studies E8, and in accordance with the 
ethical principles that have their origin in the Declaration of Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for all clinical 
interventional investigat ions sponsored by [CONTACT_19481] (parties) 
employed for their execution (e.g., contract research organizations, collaborative 
research efforts). This Code is not intended to apply to trials that are observational in 
nature, or which are retr ospective. Further, this Code does not apply to investigator -
initiated trials, which are not under the full control of MSD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -
driven to assess safety, efficacy, and/or pharmacokinetic or pharmacodynamic 
indices of MSD or comparator products. Alternatively, MSD may conduct 
outcomes research trials, trials to assess or validate various endpoint measures, or 
trials to det ermine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) must be 
adequate to address the specific purpose of the trial and shall respect the data 
protection rights of all participants, trial site staff and, wh ere applicable, third 
parties. Input may be considered from a broad range of stakeholders, including 
patient advocacy groups/patients representing the trial population, caregivers, and 
healthcare providers to ensure operational feasibility. Trial design al so includes 
08V5WQ
PRODUCT: MK-2060 95
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201826] meet 
protocol entry criteria to be enrolled in the trial.
2.Site Selection
MSD’s clinical trials are conducted globally in many different countries and in 
diverse populations, incl uding people of varying age, race, ethnicity, gender, and 
accounting for other potential disease related factors. MSD selects investigative 
sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous per formance in clinical trials, as well as budgetary 
considerations. Prior to trial initiation, sites are evaluated by [CONTACT_26397] (or 
individuals acting on behalf of MSD) to assess the ability to successfully conduct 
the trial. Individuals involved in trial conduct receive training commensurate with 
their role prior to their becoming involved in the trial.
Where appropriate, and in accordance with regulatory authority guidance, MSD 
will make concerted efforts to raise awareness of clinical trial opportuniti es in 
various communities. MSD will seek to engage underrepresented groups and 
those disproportionately impacted by [CONTACT_26398]. MSD will support 
clinical trial investigators to enroll underrepresented groups and expand access to 
those who will ultimately use the products under investigation.
3.Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol 
and Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, 
complet eness, and consistency. Data are verified versus source documentation 
according to standard operating procedures. Per MSD policies and procedures, if 
potential fraud, scientific/research misconduct, privacy incidents/breaches or 
Clinical Trial -related Sign ificant Quality Issues are reported, such matters are 
investigated. When necessary, appropriate corrective and/or preventative actions 
are defined and regulatory authorities and/or ethics review committees are 
notified.
B.Publication and Authorship
Regard less of trial outcome, MSD commits to publish the primary and secondary 
results of its registered trials of marketed products in which treatment is assigned, 
according to the pre -specified plans for data analysis. To the extent scientifically 
appropriate, MSD seeks to publish the results of other analyses it conducts that are 
important to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_326633]; in such cases, 
publication of r esults may not be appropriate since the trial may be underpowered and 
the analyses complicated by [CONTACT_19482].
08V5WQ
PRODUCT: MK-2060 96
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201827] -2023
MSD’s policy on authorship is consistent with the recommendations published by [CONTACT_19483] (ICMJE). In summary, 
authorship should reflect significant contribution to the design and conduct of the 
trial, performance or interpretation of the analysis, and/or writing of the manuscript. 
All named authors must be able to defend the trial results and conclusions. MSD 
funding of a trial will be acknowledged in publications.
III.Participant Protection
A.Regulatory Authority and Ethics Committee Review (Institutional Review Board 
[IRB]/Independent Ethics Committee [IEC])
All protocols a nd protocol amendments will be submitted by [CONTACT_113833]/authorization prior to implementation of the trial or amendment, 
in compliance with local and/or national regulations.
The protocol, protocol amendment(s), informed consent form, investigator’s 
brochure, and other relevant trial documents must be reviewed and approved by [CONTACT_113834]/IEC before being implemented at each site, in compliance with local and/or 
national regulations and ICH Guidelines. Changes to the protocol that are required 
urgently to eliminate an immediate hazard and to protect participant safety may be 
enacted in anticipation of ethics committee approval. MSD will inform regulatory 
authorities of such new measures to protect participant safety, in compliance with 
local and/or national regulations.
B.Safety
The guiding principle in decision -making in clinical trials is that participant welfare is 
of primary importance. Potential participants will be informed of the risks and 
benefits of, as well as alternatives to, trial participation. At a minimum, trial designs 
will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only 
after informed consent is obtained. Trial designs include procedur es and systems for 
the identification, monitoring, and reporting of safety concerns. Participants may 
withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
During trial planning, the need for an independent Data Monitoring Committee 
(DMC) is assessed. DMC review of data accumulated during the conduct of the trial 
is integral to the well -being of trial participants.
C.Confidentiality
MSD is committed to safeguar ding participant confidentiality, to the greatest extent 
possible, as well as all applicable data protection rights. Unless required by [CONTACT_2371], only 
the investigator, Sponsor (or individuals acting on behalf of MSD), ethics committee, 
and/or regulatory author ities will have access to confidential medical records that 
might identify the participant by [CONTACT_2300].
08V5WQ
PRODUCT: MK-2060 97
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201828] -2023
D.Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed 
consent authorized by [CONTACT_19486].
E.Trial Results
At the time of providing informed consent and in accordance with local laws and 
regulations, participants should be informed about the plans for availability of trial 
results.
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time -and labor -intensive. It is MSD’s policy to compensate 
investigators (or the sponsoring institution) in a fair manner for the work performed 
in support of MSD trials. MSD does not pay incentives to enroll participants in its 
trials . However, when enrollment is particularly challenging, additional payments 
may be made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, MSD may compensate 
referring physicians for time spen t on medical record review and medical evaluation 
to identify potentially eligible participants.
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by [CONTACT_19487], and that the 
investigator or sponsoring institution is be ing paid or provided a grant for performing 
the trial. However, the local ethics committee may wish to alter the wording of the 
disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting f rom MSD trials will indicate MSD as a source 
of funding.
C.Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (e.g., to scientific meetings, 
investigator meetings, etc) will be consistent with local guidelines and p ractices.
V.Investigator Commitment
Investigators will be expected to review MSD’s Code of Conduct as an appendix to the 
trial protocol, and in signing the protocol, agree to support these ethical and scientific 
standards.
10.1.2 Financial Disclosure
Financial disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor’s responsibility to determine, based on these regulations, whether a request for 
08V5WQ
PRODUCT: MK-2060 98
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201829] -2023
financial disclosure information is required. It is the investigator’s/subinvestigator’s 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Dis closure Form, frequently known as a financial disclosure form, provided by 
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.[ADDRESS_1201830] this study in compliance with all applicable data protection 
regulations.
Participants will be assigned a unique identifier by t he Sponsor. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
The participant must be informe d that his/her personal study -related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may be exa mined by [CONTACT_19491], by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator by [CONTACT_19492], and such information will 
be divulged to the IRB, IEC, or similar or expert committee ,affiliated institution, and 
employees , only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution ,and employees. Data generated by [CONTACT_19493], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to 
verify worksheet/CRF data. By [CONTACT_17317], the participant agrees to this 
process. If study documents will be photocopi[INVESTIGATOR_88648]/CRF information, the participant wil l be identified by [CONTACT_19494]; full 
names/initials will be masked before transmission to the Sponsor.
08V5WQ
PRODUCT: MK-2060 99
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201831] -2023
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable privacy laws, rules ,
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/ IEC meets 
regulatory and ICH GCP requirements by [CONTACT_26389]/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496].
10.1.[ADDRESS_1201832] 
proprietary information and to provide comments.
Authorship will be determined by [CONTACT_113837].
10.1.6 Compliance with Study Registration and Results Posting Requirements
Under the terms of the FDAAA of 2007 and the EMA clinical trial sRegulation 536/[ADDRESS_1201833] to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu, https://euclinicaltrials.eu , or other local registries. MSD, as 
Sponsor of this study, will review this prot ocol and submit the information necessary to 
fulfill these requirements. MSD entries are not limited to FDAAA or the EMA clinical trials 
Regulation 536/[ADDRESS_1201834] information.
By [CONTACT_12570], the investigator acknowledges that the statu tory obligations under 
FDAAA, the EMA clinical trials Regulation 536/2014, or other locally mandated registries 
are that of the Sponsor and agrees not to submit any information about this study or its results 
to those registries.
08V5WQ
PRODUCT: MK-2060 100
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201835] the study in an efficient and 
diligent manner and in conformance with this protocol ;generally accepted standards of GCP 
(eg, ICH GCP: Consolidated Guideline and other generally a ccepted standards of GCP) ;and 
all applicable federal, state ,and local laws, rules and regulations relating to the conduct of 
the clinical study.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by [CONTACT_19487], is provided in this appendix 
under the Code of Conduct for Clinical Trials.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedu res included as part of the study 
reimbursed to the investigator by [CONTACT_1034].
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations resulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submis sion to the regulatory authority.
Persons debarred from conducting or working on clinical studies by [CONTACT_19500]’s studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
For investigators located in countries with serious breach reporting requirements, investigator 
will promptly report to the Sponsor any serious breach or suspected serious breach that 
occurs in compliance with those requirements. Unless more specifically defined in the 
applicable requirements, a serious breach is any breach of the applicable clinical trial 
regulation or of the clinical trial protocol which is likely to affect to a significant degree: (i) 
the safety or rights of a trial participant, or (ii) the reliability and robustness of the data 
generated in the clinical trial.
10.1.8 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verifying that data entries are accurate and correct by 
[CONTACT_1189].
Detailed information regarding Data Management procedures for this protocol will be 
provided separately.
08V5WQ
PRODUCT: MK-2060 101
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201836] maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data docume nts.
Study documentation will be promptly and fully disclosed to the Sponsor by [CONTACT_63551], 
copying, review, and audit at reasonable times by [CONTACT_19502]. The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_19503] a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs.
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including participants’ documented informed consent, pertaining to 
the conduct of this study must be retained by [CONTACT_1732] 15 years after study 
complet ion unless local regulations or institutional policies require a longer retention period. 
No records may be destroyed during the retention period without the written approval of the 
Sponsor. No records may be transferred to another location or party withou t written 
notification to the Sponsor.
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator/institution should maintain adequate and 
accurate source d ocuments and study records that include all pertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator/institution may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available.
08V5WQ
PRODUCT: MK-2060 102
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201837] -2023
10.1.10 Study and Site Closure
The Sponsor or its designee may stop the study or study -site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor premature ly terminates a particular study site, the Sponsor or 
designee will promptly notify that study site’s IRB/IEC as specified by [CONTACT_88714](s).
08V5WQ
PRODUCT: MK-2060 103
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201838] -2023
10.2 Appendix 2: Clinical Laboratory Tests
•The tests detailed in Table 10will be performed by [CONTACT_12082].
•Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
•Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_11006].
Table 10 Protocol -required Safety Laboratory Assessments
Laboratory 
Assessments Parameters
Hematology Platelet Count RBC Indices:
MCV
MCH
%ReticulocytesWBC count with 
Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hemoglobin
Hematocrit
Chemistry BUN Potassium AST/SGOT Total bilirubin (and 
direct bilirubin if 
total bilirubin is 
above the upper 
limit of normal)
Albumin Bicarbonate Chloride Phosphorous
Creatinine Sodium ALT/SGPT Total Protein
Glucose Calcium Alkaline 
phosphatase
Coagulation aPTT, PT
Routine 
Urinalysis •Specific gravity
•pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte 
esterase by [CONTACT_5230]
•Microscopic examination (if blood or protein is abnormal)
Other Urine 
Tests•24-hour urine collection for urine protein
•24-hour urine collection for urine creatinine
•Spot urine protein: urine creatinine ratio
08V5WQ
PRODUCT: MK-2060 104
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201839] -2023
Laboratory 
Assessments Parameters
Other Screening 
Tests •FSH, as needed in WONCBP only
•Alcohol and drug screen (to include at minimum: amphetamines, barbiturates, 
cocaine, opi[INVESTIGATOR_858], cannabinoids, and benzodiazepi[INVESTIGATOR_1651]) 
•Serology (HIV antibody, HBsAg, and hepatitis C virus antibody)
•Serum β human chorionic gonadotropin (β hCG) pregnancy test (as needed for 
female participant)
ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; FSH=follicle -
stimulating hormone; HBsAg=hepatitis B surface antigen; hCG=human chorionic gonadotropin; [HIV=human 
immunodeficiency vi rus]; MCH=mean corpuscular hemoglobin; MCV=mean corpuscular volume; RBC=red 
blood cell; SGOT=serum glutamic -oxaloacetic transaminase; SGPT=serum glutamic- pyruvic transaminase; 
ULN=upper limit of normal; WBC=white blood cell; WOCBP=women of childbearing pot ential; 
WONCBP=women of nonchildbearing potential
The investigator (or medically qualified designee) must document their review of each 
laboratory safety report.
08V5WQ
PRODUCT: MK-2060 105
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201840] -2023
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recordin g, 
Evaluating, Follow -up, and Reporting
10.3.[ADDRESS_1201841].
10.3.2 Definition of AE
AE definition
•An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
•Note: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated ) temporally 
associated with the use of a study intervention.
•Note: For purposes of AE definition, study intervention includes any pharmaceutical 
product, biological product, vaccine, diagnostic agent, medical device, combination 
product, or protocol -speci fied procedure whether investigational or marketed (including 
placebo, active comparator product, or run -in intervention), manufactured by, licensed 
by, provided by, or distributed by [CONTACT_63553].
Events meeting the AE definition
•Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency and/or intensity of the condition.
08V5WQ
PRODUCT: MK-2060 106
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201842] -2023
•New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
interventi on or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnorma l laboratory results is reported using 
the terminology “accidental or intentional overdose without adverse effect.”
•Any new cancer or progression of existing cancer.
Events NOT meeting the AE definition
•Medical or surgical procedure (eg, endoscopy, append ectomy): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s ) present or 
detected at the start of the study that do not worsen.
•Surgical procedure(s) planned prior to informed consent to treat a preexisting condition 
that has not worsened.
•Refer to Section 8.4.[ADDRESS_1201843] medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
- The term “life- threatening” in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
08V5WQ
PRODUCT: MK-2060 107
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201844] -2023
c.Requires inpatient hospi[INVESTIGATOR_1081]
-Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a preexisting condition that has not 
worsened is not an SAE.) A preexisting condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history.
d.Results in persistent or significant disability/incapacity
-The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
-This definition is not intended to include experiences of relatively minor medical 
signi ficance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/ birth defect
-In offspring of participant taking the product regardless of time to diagnosis.
f.Other important medical events
-Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as i mportant medical events that may 
not be immediately life -threatening or result in death or hospi[INVESTIGATOR_63474] 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
-Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias ,or 
convulsions that do not result in hospi[INVESTIGATOR_1916], or development of drug dependency 
or drug abuse.
10.3.4 Additional Events Reported
Additional events that require reporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are report able to the Sponsor.
•Is a cancer .
•Is associated with an overdose .
08V5WQ
PRODUCT: MK-2060 108
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201845] -2023
10.3.5 Recording AE and SAE
AE and SAE recording
•When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs/worksheets at each examination.
•It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medica l 
records to the Sponsor in lieu of completion of the AE CRF page.
•There may be instances when copi[INVESTIGATOR_88650]. In this case, all participant identifiers, with the exception of the participant 
number , will be blinded on the copi[INVESTIGATOR_19361].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of intensity /toxicity
•An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity for each AE and SAE (and other 
reportable safety event) reported during the study and assign it to 1 of the following 
categories:
-Mild: An event that is easily tolerated by [CONTACT_2299], causing minima l discomfort, 
and not interfering with everyday activities (for pediatric studies, awareness of 
symptoms, but easily tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
everyday activities (for pediatric studies, defin itely acting like something is wrong).
-Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category used for rating the 
intensity of an event; and both AE and SAE can be assessed as severe (for pediatric 
studies, extremely distressed or unable to do usual activities).
Assessment of causality
•Did the Study intervention cause the AE?
08V5WQ
PRODUCT: MK-2060 109
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201846] -2023
•The determination of the likelihood that the Study intervention caused the AE will be 
provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done. This initialed 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
Study intervention and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity), the more likely the Sponsor’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actually exposed to the Study 
intervention such as: reliable history, acceptable compliance assessment (pi[INVESTIGATOR_692], 
diary, etc), expected pharmacologic effect, or measurement of drug/metabolite in 
bodily specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Study intervention ? Is the time of onset of the AE compatible 
with a drug -induced effect (applies to studies with investigational medicinal product)?
-Likely Cause: Is the AE not reasonably explained by [CONTACT_19511], other drug(s)/vaccine(s), or other host or environmental factors.
-Dechallenge: Was the Study intervention discontinued or dose/exposure/frequency 
reduced?
◦If yes, did the AE resolve or improve?
◦If yes, this is a positive dechallenge.
◦If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent di sability; 
(2) the AE resolved/improved despi[INVESTIGATOR_861891] ; (3) the study is 
a single -dose drug study; or (4) Study intervention (s) is/are only used 1 time.)
-Rechallenge: Was the participant re -exposed to the Study intervention in this study?
◦If yes, did the AE recur or worsen?
◦If yes, this is a positive rechallenge.
◦If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent 
disability, or (2) the study is a single -dose drug study; or (3) Study intervention (s) is/are used 
only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_19512], OR IF RE -
EXPOSURE TO THE STUDY INTERVENTION POSES ADDITIONAL PO TENTIAL 
SIGNIFICANT RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE 
APPROVED IN ADVANCE BY [CONTACT_93333], AND IF 
REQUIRED, THE IRB/IEC.
08V5WQ
PRODUCT: MK-2060 110
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201847] -2023
•Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the Study intervention or drug class 
pharmacology or toxicology?
•The assessment of relationship will be reported on the CRFs/worksheets by [CONTACT_26368] a qualified physician according to their best clini cal judgment, 
including consideration of the above elements.
•Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Study intervention relationship).
-Yes, there is a reasonable possibility of Study intervent ionrelationship:
◦There is evidence of exposure to the Study intervention . The temporal sequence 
of the AE onset relative to the administration of the Study intervention is 
reasonable. The AE is more likely explained by [CONTACT_861905].
-No, there is not a reasonable possibility of Study intervention relationship:
◦Participant did not receive the Study intervention OR temporal sequence of the 
AE onset relative to administration of the Study intervention is not reasonable OR 
the AE is more likely explained by [CONTACT_861906] . 
(Also entered for a participant with overdose without an associated AE.)
•The investigator must review and provide an assessment of causality for each AE/SAE 
and document this in the me dical notes.
•There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causality for e very event before the 
initial transmission of the SAE data to the Sponsor.
•The investigator may change their opi[INVESTIGATOR_9242]- up information 
and send an SAE follow- up report with the updated causality assessment.
•The causality assessment is 1 of the criteria used when determining regulatory reporting 
requirements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any updated SAE data to the Sponsor within [ADDRESS_1201848]: MK-2060 111
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201849] -2023
10.3.6 Reporting of AEs, SAEs, and Other Reportable Safety Events to the Sponsor
AE, SAE, and other reportable safety event reporting to Sponsor via electronic data 
collection tool
•The primary mechanism for reporting to the Sponsor will be the EDC tool.
-Electronic reporting procedures can be found in the EDC data entry guidelin es (or 
equivalent).
-If the electronic system is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
-Reference Section 8.4.1 for reporting time requirements.
•The site will enter the SAE data into the electronic system as soon as it becomes 
available.
•After the study is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry of new data or changes to existing data.
•If a site receives a report of a new SAE from a study participant or receives upda ted data 
on a previously reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
•Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure email of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by [CONTACT_19515].
•Initial notification via telephone does not replace the need for the investigator to 
complet e and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent).
08V5WQ
PRODUCT: MK-2060 112
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201850] -2023
10.4 Appendix 4: Medical Device and Drug–Device Combination Products: Product 
Quality Complaints/Malfunctions: Definitions, Recording, and Follow -up
Not applicable.
08V5WQ
PRODUCT: MK-2060 113
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201851] -2023
10.5 Appendix 5: Contraceptive Guidance
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below):
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstru al cycle cannot 
be confirmed before first dose of study intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
◦A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of [ADDRESS_1201852]: MK-2060 114
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201853] -2023
Women of Nonchildbearing Potential (WONCBP)
Women in the following categories are considered WONCBP:
•Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note:  Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausa l state is defined as no menses for 12 months without an alternative 
medical cause. 
◦A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of [ADDRESS_1201854] discontinue HRT to 
allow confirmation of postmenopausal status before study enrollment.
10.5.2 Contraceptive Requirements
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctl y.
•Progestogen -only contraceptive implantd
•IUSe
•Non-hormonal IUD
•Bilateral tubal occlusion
•Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of 
the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoospermia for a male participant can come from the site personnel’s review of 
the participant’s medical records, medical examination, or medical history interview.
08V5WQ
PRODUCT: MK-2060 115
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201855] -2023
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when used consistently and correctly.
•Combined (estrogen -and progestogen -containing) hormonal contraceptiond
-Oral
-Intravaginal
-Transdermal
-Injectable
•Progestogen -only hormonal contraceptiond
-Oral
-Injectable
Sexual Abstinence
•Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and u sual lifestyle 
of the participant.
Methods That Are Not Considered Highly Effective
Failure rate of >1% per year when used consistently and correctly.
•Progesterone- only hormonal contraception where inhibition of ovulation is not the primary mode of action
•Male or female condom with or without spermicide
•Cervical cap, diaphragm, or sponge with spermicide
•A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double 
barrier methods) .
a   Contraceptive use by [CONTACT_93339].
b   Typi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and correctly).
d  If locally required, in accordance with CTFG guidelines, acceptable hormonal contraceptives are limited to 
those which inhibit ovulation.
e   IUS is a progestin releasing IUD.
Note: The following are not acceptable methods of contraception:
-  Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus 
interruptus), spermicides only, and LAM.
-  Male and female condom should not be used together (due to risk of failure with friction ).
08V5WQ
PRODUCT: MK-2060 116
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201856] -2023
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
a.Biomarker: A biological molecule found in blood, other body fluids, or tissues that is 
a sign of a normal or abnormal process or of a condition or disease. A biomarker may 
be used to see how well the body responds to a treatment for a disease or condition.1
b.Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
c.Pharmac ogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
d.DNA: Deoxyribonucleic acid.
e.RNA: Ribonucleic acid.
2.Scope of Future Biomedical Research3, 4
The specimens consented and/or collected in this study as outlined in Section 8.9will be 
used in various experiments to understand:
-The biology of how drugs/vaccines work
-Biomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_10489]
-Other pathways with which drugs/vaccines may interact
-The biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease ,and ultimately 
improve public health through development of novel treatments targeted to populations 
with t he greatest need. All specimens will be used by [CONTACT_63558].
3.Summary of Procedures for Future Biomedical Research3, 4
a.Participants for Enrollment
All participants enrolled in the clinical study will be consid ered for enrollment in 
future biomedical research.
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc) will be obtained during 
screening for protocol enrollment from all participants or legal guardians, at a study 
visit by [CONTACT_941] i nvestigator or his or her designate. Informed consent for future 
biomedical research should be presented to the participants on the visit designated in 
the SoA. If delayed, present consent at next possible Participant Visit. Consent forms 
signed by [CONTACT_861907].
08V5WQ
PRODUCT: MK-2060 117
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201857] -2023
A template of each study site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository.
c.eCRF Documentation for Future Biomedica l Research Specimens
Documentation of participant consent for future biomedical research will be captured 
in the eCRFs. Any specimens for which such an informed consent cannot be verified 
will be destroyed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical research will be performed as outlined 
in the SoA. In general, if additional blood specimens are being collected for future 
biomedical research, these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4.Confidential Participant Information for Future Biomedical Research3, 4
In order to optimize the research that can be conducted with future biomedical research 
specimens, it is critical to link participants ’clinical information with future test results. In 
fact, little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characte ristics like sex, age, medical history ,and intervention outcomes is
critical to understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for future 
biomedical research, the Sponsor has deve loped secure policies and procedures. All 
specimens will be single coded per ICH E15 guidelines as described below.
At the clinical study site, unique codes will be placed on the future biomedical research 
specimens. This code is a random number thatdoes not contain any personally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study site. No personal identifiers will 
appear on the specimen tube.
5.Biorepository Specime n Usage3, [ADDRESS_1201858] party (eg, a university investigator) designated by [CONTACT_429]. The investigator conducting the analysis will follow the Sponsor’s privacy and 
confidentiality requirements. Any contracted third -party analyses will conform to the 
specific scope of analysis outlined in future biomedical researc h protocol and consent. 
Future biomedical research specimens remaining with the third party after specific 
analysis is performed will be reported to the Sponsor.
6.Withdrawal From Future Biomedical Research3, [ADDRESS_1201859] the Sponsor using the designate d mailbox 
(clinical.specimen.management@ MSD .com). Subsequently, the participant's specimens 
will be flagged in the biorepository and restricted to study use only. If specimens were 
08V5WQ
PRODUCT: MK-2060 118
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201860] -2023
collected from study participants specifically for FBR, these specimens wil l be removed 
from the biorepository and destroyed. Documentation will be sent to the investigator 
confirming withdrawal and/or destruction, if applicable. It is the responsibility of the 
investigator to inform the participant of completion of the withdrawa l and/or destruction, 
if applicable. Any analyses in progress at the time of request for withdrawal/destruction 
or already performed before the request being received by [CONTACT_861908]. No new analyses would be 
generated after the request is received.
If the medical records for the study are no longer available (eg, if the investigator is no 
longer required by [CONTACT_88692]) or the specimens 
have been completely anonymized, there will no longer be a link between the 
participant’s personal information and their specimens. In this situation, the request for 
withdrawal of consent and/or destruction cannot be processed.
7.Retention of Specimens3, [ADDRESS_1201861] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants3, [ADDRESS_1201862]: MK-2060 119
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201863] security, policies, and procedures to address participant 
data privacy concerns. Data privacy risks are largely limited to rare situations involving 
possible breach of confidentiality. In this highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
12.Questions
Any questions related to the future biomedical research should be emailed directly to 
clinical.specimen.management@ MSD .com.
13.References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.International Council on Harmonisation [Internet]: E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Availabl e from 
http://www.ich.org/products/guidelines/efficacy/efficacy -single/article/definitions -
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html
3.Industry Pharmacogenomics Working Group [Internet]: Understanding the In tent, 
Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/
4.Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure fo r IRBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/
08V5WQ
PRODUCT: MK-2060 120
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201864] -2023
10.7 Appendix 7: Country -specific Requirements
Not applicable.
08V5WQ
PRODUCT: MK-2060 121
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201865] -2023
10.8 Appendix 8: Blood Volume Table s
Part 1
PrestudyTreatment 
Periods PoststudyTotal 
CollectionsmL Per 
CollectionTotal 
mL/ Test
Laboratory Safety Tests 2 4 1 7 12.5 87.5
HIV/Hepatitis Screen (at the 
discretion of the investigator)1 0 0 1 5 5
Blood for Planned Genetic 
Analysis0 1 0 1 8.5 8.5
FSH (Females only) [ADDRESS_1201866] 
(Females only)1 1 1 3 3.5 10.5
Blood for plasma ADA and 
MK-[ZIP_CODE] 5 1 6 2.7 16.2
Blood for PT and aPTT at local 
lab1 6 0 7 3 21
Blood for PT, aPTT, and Factor 
XI activity at central lab0 12 1 13 10 130
Blood for MK-2060 only 0 7 0 7 1.8 12.6
Total Blood Volume per Male Participanta280.8 mL
Total Blood Volume per Female Participanta294.8 mL
ADA=anti -drug antibody; aPTT=activated partial thromboplastin time; hCG=human chorionic gonadotropin; 
HIV=human immunodeficiency virus; PT=prothrombin time
aIf additional pharmacokinetic/pharmacodynamic and/or safety analysis is necessary, additional blood (no more than 
50mL in total) may be obtained.
Part 2
PrestudyTreatment 
Periods PoststudyTotal 
CollectionsmL Per 
CollectionTotal 
mL/ Test
Laboratory Safety Tests 2 10 1 13 12.5 162.5
HIV/Hepatitis Screen (at the 
discretion of the investigator)1 0 0 1 5 5
Blood for Planned Genetic 
Analysis0 1 0 1 8.5 8.5
FSH (Females only) [ADDRESS_1201867] 
(Females only)1 2 1 4 3.5 14
Blood for plasma ADA and 
MK-[ZIP_CODE] 7 1 8 2.7 21.6
Blood for PT and aPTT at local 
lab1 7 1 9 3 27
Blood for PT, aPTT, and Factor 
XI activity at central lab0 16 1 17 10 170
Blood for MK-2060 only 0 9 0 9 1.8 16.2
Total Blood Volume per Male Participanta410.8 mL
Total Blood Volume per Female Participanta428.3 mL
ADA=anti -drug antibody; aPTT=activated partial thromboplastin time; hCG=human chorionic gonadotropin; 
HIV=human immunodeficiency virus; PT=prothrombin time
aIf additional pharmacokinetic/pharmacodynamic and/or safety analysis is necessary, additional blood ( no 
more than 50 mLin total ) may be obtained.
08V5WQ
PRODUCT: MK-2060 122
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201868] -2023
Part 3
PrestudyTreatment 
Periods PoststudyTotal 
CollectionsmL Per 
CollectionTotal 
mL/ Test
Laboratory Safety Tests 2 4 1 7 12.5 87.5
HIV/Hepatitis Screen (at the 
discretion of the investigator)1 0 0 1 5 5
Blood for Planned Genetic 
Analysis0 1 0 1 8.5 8.5
FSH (Females only) [ADDRESS_1201869] 
(Females only)1 1 1 3 3.5 10.5
Blood for plasma ADA and 
MK-[ZIP_CODE] 7 1 8 2.7 21.6
Blood for PT and aPTT at local 
lab1 6 0 7 3 21
Blood for PT, aPTT, and Factor 
XI activity at central lab0 14 1 15 10 150
Blood for MK-2060 only 0 7 0 7 1.8 12.6
Total Blood Volume per Male Participanta306.2 mL
Total Blood Volume per Female Participanta320.2 mL
ADA=anti -drug antibody; aPTT=activated partial thromboplastin time; hCG=human chorionic gonadotropin; 
HIV=human immunodeficiency virus; PT=prothrombin time
aIf additional pharmacokinetic/pharmacodynamic and/or safety analysis is necessary, additional blood ( no 
more than 50 mLin total ) may be obtained.
08V5WQ
PRODUCT: MK-2060 123
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201870] -2023
10.9 Appendix 9: Algorithm for Assessing Out of Range Laboratory Values
For all laboratory values obtained at pre -study (screening) visit and/or pre -dose evaluation:
a.If all protocol- specified laboratory values are normal, the participant may enter the study.
b.If a protocol specified laboratory value is outside of the parameter(s) outlined in the 
inclusion/exclusion criteria (including a repeat if performed), the participant will be 
excluded from the study.
c.If ≥1 protocol -specifi ed laboratory value not specified in the inclusion/exclusion criteria 
is outside the normal range, the following choices are available:
a.The participant may be excluded from the study.
b.The participant may be included in the study if the abnormal value(s) is NCS (the 
investigator must annotate the laboratory value “NCS” on the laboratory safety test 
source document).
c.The participant may be included in the study if the abnormality is consistent with a 
pre-existing medical condition which is not excluded per protocol (e.g., elevated 
eosinophil count in a participant with asthma or seasonal allergies), the medical 
condition should be annotated on the laboratory report.
OR
d.The abnormal test may be repeated (refer items a. and b. below for continuation of 
algorithm for repeated values).
a.If the repeat test value is within the normal range, the participant may enter the 
study.
b.If the repeat test value is still abnormal, the study investigator will evaluate the 
potential participant with a complete history and physical examination, looking 
especially for diseases that could result in the abnormal laboratory value in 
question. If such diseases can be ruled out, and if the abnormal laboratory value is 
not clinically relevant, then the participant may enter the study.
d.If there is any clinical uncertainty regarding the significance of an abnormal value, the 
participant will be excluded from the study.
08V5WQ
PRODUCT: MK-2060 124
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201871] -2023
10.10 Appendix 10: Abbreviations
Abbreviation Expanded Term
Ab antibody
ACE angiotensin converting enzyme
ADA anti-drug antibodies
AE adverse event 
ALP alkaline phosphatase
ALT alanine aminotransferase
aPTT activated partial thromboplastin time
AS anti-sense oligo
AST aspartate aminotransferase
AUC area under the concentration -time curve
AUC0 -∞ area under the concentration -time curve extrapolated to infinity
AUC0 -[ADDRESS_1201872] measurable 
conce ntration
AV arteriovenous
AVG arteriovenous graft
BMI body mass index
BP blood pressure
C plasma concentration
C168 concentration at 168 hours
CCU Critical Care Unit
CI confidence interval
Cmax maximum plasma concentration
CKD Chronic Kidney Disease
CKD4 Stage 4 Chronic Kidney Disease
CKD5 Stage 5 Chronic Kidney Disease
CKD -EPI [INVESTIGATOR_827383]/F apparent total clearance
COVID -[ADDRESS_1201873]: MK-2060 125
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201874]
FGA Fibrin Generation Assay
FSH follicle -stimulating hormone 
FXa Factor Xa
FXI Factor XI
FXIa Factor XIa
GCP Good Clinical Practice 
GCV geometric coefficient of variation
GI gastrointestinal
GLP -1 glucagon -like peptide 1
GM geometric mean
GMR geometric mean ratio
HBcAb hepatitis B core antibody
HBsAg hepatitis B surface antigen
HBV hepatit is B virus
hCG human chorionic gonadotropin
HCV hepatitis C virus
HD hemodialysis
HIV human immunodeficiency virus
HR heart rate
IB Investigator’s Brochure 
ICF Informed Consent Form
ICH International C ouncil for Harmoni sation of Technical Requirements for 
Pharmaceuticals for Human Use
ICU Intensive Care Unit
IEC Independent Ethics Committee
Ig immunoglobulin
IgG4 immunoglobulin G4
IND Investigational New Drug 
INR International Normalized Ratio
IRB Institutional Review Board
IUD intrauterine device
IV intravenous
IVIG intravenous immune globulin
08V5WQ
PRODUCT: MK-2060 126
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201875] level 
NSAID nonsteroidal anti -inflammatory drug(s)
OTC over-the-counter
P protocol (number)
PCL Protocol Clarification Letter
PK pharmacokinetic
PI [INVESTIGATOR_861892]-protocol
PR PR interval
PT prothrombin time
QTc Q-T corrected (corrected Q -T interval)
QW once weekly
RhoGAM A brand of Rh immunoglobulin
RNA ribonucleic acid
RR respi[INVESTIGATOR_861893] (ly)
SD standard deviation
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SoA schedule of activities
SOC standard of care
SOP Standard Operating Procedures
S[LOCATION_003]R suspected unexpected serious adverse reaction
t1/[ADDRESS_1201876] upper limit of normal
uPCR urine protein to creatinine ratio
USP [LOCATION_002] Pharmacopeia
Vd volume of distribution
VS vital signs
Vz/F apparent volume of distribution
WOCBP woman/women of childbearing potential
WONCBP woman/women of nonchildbearing potential
08V5WQ
PRODUCT: MK-2060 127
PROTOCOL/AMENDMENT NO.: 011-[ADDRESS_1201877] -2023
11 REFERENCES
[Bethune, C., et al 2017] Bethune C, Walsh M, Jung B, Yu R, Geary 
RS, Bhanot S. Pharmacokinetics and 
pharmacodynamics of Ionis -FXI(RX), an 
antisense inhibitor of factor XI, in patients 
with end -stage re nal disease on 
hemodialysis. Blood. 2017;130:1116.[0559X2]
[Buller, H. R., et al 2015] Buller HR, Bethune C, Bhanot S, Gailani D, 
Monia BP, Raskob GE, et al. Factor XI 
antisense oligonucleotide for prevention of 
venous thrombosis. N Engl J Med. 2015 Jan 
15;372(3):232- 40.[04T0MV]
08V5WQ